



**Keystone 65 Rx HMO
Personal Choice 65SM Rx
PPO Select Option[®] Rx PDP
2026 Utilization Management
Criteria: Prior Authorization**

**PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION
ABOUT SOME OF THE DRUGS WE COVER IN THIS PLAN**

This document was updated on **10/15/2025**. For more recent information or other questions, please contact our Member Help Team: Keystone 65 Rx at **1-844-352-1699**, Personal Choice 65 Rx at **1-888-879-4293**, Select Option Rx at **1-888-678-7009** or, for TTY/TDD users, **711**, seven days a week from 8 a.m. to 8 p.m. Please note that on weekends and holidays from April 1 through September 30, your call may be sent to voicemail. Or, visit www.ibxmedicare.com to use our *Formulary (List of Covered Drugs)* search tool or view a downloadable document.

When this document refers to “we,” “us,” or “our,” it means Independence Blue Cross. When it refers to “plan” or “our plan,” it means Keystone 65 Rx, Personal Choice 65 Rx, and Select Option Rx.

You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1, 2027, and from time to time during the year.

Independence Blue Cross offers HMO and HMO-POS Medicare Advantage plans with a Medicare contract. Enrollment in Independence Blue Cross HMO and HMO-POS Medicare Advantage plans depends on contract renewal.

Independence Blue Cross offers products through its subsidiaries Independence Assurance Company, Independence Hospital Indemnity Plan, Keystone Health Plan East, and QCC Insurance Company — independent licensees of the Blue Cross and Blue Shield Association.

There may be restrictions to your drug coverage

Some covered drugs may have additional requirements or limits on coverage. We call this “utilization management.” These requirements and limits may include:

- **Prior Authorization (PA):** Our plan requires you or your physician to get prior authorization for certain drugs. This means that you will need to get approval from our plan before you fill your prescriptions. If you don’t get approval, our plan may not cover the drug. Drugs that require prior authorization are listed in this document.
- **Step Therapy (ST):** In some cases, our plan requires you to first try certain drugs to treat your medical condition before we will cover another drug for that condition. Drugs that require step therapy are listed in *2026 Utilization Management Criteria: Step Therapy*.
- **Quantity Limits (QL):** For certain drugs, our plan limits the amount of the drug that our plan will cover. Drugs that have quantity limits are listed in the *Keystone 65 Rx, Personal Choice 65 Rx, and Select Option Rx Formulary (List of Covered Drugs)*.

You can find out if your drug has any additional requirements or limits by looking in your plan *Formulary (List of Covered Drugs)*. You can also get more information about the restrictions applied to specific covered drugs by visiting www.ibxmedicare.com.

You can ask our plan to make an exception to these restrictions or limits, or for a list of other similar drugs that may treat your health condition. Your *Formulary (List of Covered Drugs)* and *Evidence of Coverage* will have more information about the exception request process.

How to use this document

This document, along with *2026 Utilization Management Criteria: Step Therapy*, is intended to be used with your *Formulary (List of Covered Drugs)*. If your prescription drug has the note “PA” in the “Requirements” column of the *Keystone 65 Rx, Personal Choice 65 Rx, and Select Option Rx Formulary (List of Covered Drugs)*, you can find more information on the restriction(s) in this document.

Locate your drug in the index on page 349. The restriction information includes:

- **Prior Authorization**
 - Covered uses
 - Exclusion criteria
 - Required medical information
 - Age restrictions
 - Prescriber restrictions
 - Coverage duration
 - Other criteria

Be sure to read all the information listed for your affected drug. If you have any questions or need assistance with the information contained in this document, please call our Member Help Team: Keystone 65 Rx at **1-844-352-1699**, Personal Choice 65 Rx at **1-888-879-4293**, or Select Option Rx at **1-888-678-7009** or, for TTY/TDD users, **711**.

ABUSE DETERRENT OPIOID 2026

Products Affected

- *hydrocodone bitartrate er oral capsule extended release 12 hour*
- *hydrocodone bitartrate er oral tablet er 24 hour abuse-deterrent*
- HYSINGLA ER ORAL TABLET ER 24 HOUR ABUSE-DETERRENT 20 MG, 30 MG, 40 MG, 60 MG, 80 MG
- NUCYNTA ER
- *oxycodone hcl oral tablet abuse-deterrent*
- OXYCONTIN ORAL TABLET ER 12 HOUR ABUSE-DETERRENT
- ROXYBOND
- XTAMPZA ER

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ACTHAR HP 2026

Products Affected

- ACTHAR
- ACTHAR GEL SUBCUTANEOUS PEN-INJECTOR
- CORTROPHIN
- CORTROPHIN GEL

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ACUTE HAE AGENTS 2026

Products Affected

- BERINERT
- FIRAZYR SUBCUTANEOUS SOLUTION
PREFILLED SYRINGE
- *icatibant acetate subcutaneous solution prefilled* syringe
- RUCONEST
- SAJAZIR SUBCUTANEOUS SOLUTION PREFILLED
SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

ACUTE SEIZURE ACTIVITY AGENTS 2026

Products Affected

- NAYZILAM
- VALTOCO 10 MG DOSE
- VALTOCO 15 MG DOSE NASAL LIQUID THERAPY PACK 2 X 7.5 MG/0.1ML
- VALTOCO 20 MG DOSE NASAL LIQUID THERAPY PACK 2 X 10 MG/0.1ML
- VALTOCO 5 MG DOSE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Prescriber is a neurologist/epilepsy specialist
Coverage Duration	Indefinite
Other Criteria	(All Indications): Approve for continuation of therapy.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

ADALIMUMAB NON-PREFERRED PRODUCTS 2026

Products Affected

- ABRILADA (1 PEN)
- ABRILADA (2 SYRINGE)
- *adalimumab-aaty (1 pen) subcutaneous auto-injector kit 80 mg/0.8ml*
- *adalimumab-aaty (2 pen)*
- *adalimumab-aaty (2 syringe)*
- *adalimumab-aaty cd/uc/hs start*
- *adalimumab-adaz*
- *adalimumab-adbm (2 pen)*
- *adalimumab-adbm (2 syringe)*
- *adalimumab-adbm(cd/uc/hs strt) subcutaneous auto-injector kit 40 mg/0.4ml*
- *adalimumab-adbm(ps/uv starter)*
- *adalimumab-fkjp (2 pen)*
- *adalimumab-fkjp (2 syringe)*
- *adalimumab-ryvk (2 pen)*
- *adalimumab-ryvk (2 syringe)*
- AMJEVITA SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- AMJEVITA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 40 MG/0.4ML, 40 MG/0.8ML
- AMJEVITA-PED 10KG TO <15KG
- AMJEVITA-PED 15KG TO <30KG
- CYLTEZO (2 PEN)
- CYLTEZO (2 SYRINGE)
- CYLTEZO-CD/UC/HS STARTER
- CYLTEZO-PSORIASIS/UV STARTER
- HADLIMA
- HADLIMA PUSHTOUCH
- HULIO (2 PEN)
- HULIO (2 SYRINGE)
- HUMIRA (2 PEN) SUBCUTANEOUS AUTO-INJECTOR KIT
- HUMIRA (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML
- HUMIRA-CD/UC/HS STARTER SUBCUTANEOUS AUTO-INJECTOR KIT 80 MG/0.8ML
- HUMIRA-PSORIASIS/UEIT STARTER SUBCUTANEOUS AUTO-INJECTOR KIT
- HYRIMOZ SUBCUTANEOUS SOLUTION AUTO-INJECTOR 40 MG/0.4ML, 80 MG/0.8ML
- HYRIMOZ SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML
- HYRIMOZ-CROHNS/UC STARTER
- HYRIMOZ-PED<40KG CROHN STARTER
- HYRIMOZ-PED>=40KG CROHN START
- HYRIMOZ-PLAQ PSOR/UEIT START
- SIMLANDI (1 PEN) SUBCUTANEOUS AUTO-INJECTOR KIT 80 MG/0.8ML
- SIMLANDI (1 SYRINGE)
- SIMLANDI (2 PEN)
- SIMLANDI (2 SYRINGE)
- YUFLYMA (1 PEN)
- YUFLYMA (2 SYRINGE)
- YUFLYMA-CD/UC/HS STARTER

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW

PA Criteria	Criteria Details
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ADALIMUMAB PREFERRED PRODUCTS 2026

Products Affected

- *adalimumab-aacf (2 pen)*
- *adalimumab-aacf (2 syringe)*
- *adalimumab-aacf(cd/uc/hs strt)*
- *adalimumab-aacf(ps/uv starter)*

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ADBRY 2026

Products Affected

- ADBRY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Atopic Dermatitis (AD)(Initial): (1) Diagnosis of moderate to severe AD (2) inadequate response or inability to tolerate ONE of the following: (a) one topical steroid (medium potency or higher) (b) topical tacrolimus (c) pimecrolimus cream
Age Restrictions	
Prescriber Restrictions	(AD): Prescribed by or in consultation with a dermatologist, allergist, immunologist
Coverage Duration	12 months
Other Criteria	(AD)(Reauth): Member has had a positive clinical response to therapy.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ADEMPAS 2026

Products Affected

- ADEMPAS

PA Criteria	Criteria Details
Exclusion Criteria	(PAH, CTEPH) (Initial, Reauth): Concurrent use of phosphodiesterase inhibitors, nitrates or nitric oxide donors, pregnancy, concurrent use with other soluble guanylate cyclase stimulators (e.g. Verquvo)
Required Medical Information	Pulmonary Arterial Hypertension (PAH) (initial): (1) Diagnosis of PAH WHO Group I with New York Heart Association (NYHA) Functional Class II - IV. (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography. (3) Documentation of all the following: (a) Mean pulmonary arterial pressure is greater than 20 mm Hg. (b) Pulmonary vascular resistance (PVR) is greater than 2.0 Woods Units (WU). (c) The pulmonary capillary wedge pressure or left ventricular end-diastolic pressure is 15 mm Hg or less. Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (initial): (1) Diagnosis of persistent/recurrent CTPH (WHO Group 4) after surgical treatment or inoperable CTEPH.
Age Restrictions	(PAH, CTEPH) Member is 18 years of age or older
Prescriber Restrictions	(PAH, CTEPH): Prescribed by or in consultation with a pulmonologist or cardiologist
Coverage Duration	(Initial): 6 months (Reauth):12 months
Other Criteria	(PAH, CPTEH) (Reauth): Stabilization or improvement as evaluated by a cardiologist or pulmonologist.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AFREZZA 2026

Products Affected

- AFREZZA INHALATION POWDER 12 UNIT, 4 UNIT, 60X4 & 60X8 & 60X12 UNIT, 8 UNIT, 90 X 4 UNIT & 90X8 UNIT, 90 X 8 UNIT & 90X12 UNIT

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AGAMREE 2026

Products Affected

- AGAMREE

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIMOVIG 2026

Products Affected

- AIMOVIG

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AJOVY 2026

Products Affected

- AJOVY

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ALLERGEN SPECIFIC IMMUNOTHERAPY (SL) 2026

Products Affected

- GRASTEK
- ODACTRA

PA Criteria	Criteria Details
Exclusion Criteria	(1) Severe, unstable or uncontrolled asthma (2) History of eosinophilic esophagitis
Required Medical Information	(Initial): (1) Member has a positive skin test or in vitro test for the listed allergen-specific IgE antibody. (2) Inadequate response or inability to tolerate an intranasal corticosteroid and an oral or intranasal antihistamine.
Age Restrictions	
Prescriber Restrictions	Prescribed by or in consultation with an allergist or immunologist.
Coverage Duration	Remainder of contract year
Other Criteria	(Reauth): (1) Member has experienced improvement in the symptoms of their allergic rhinitis or a decrease in the number of medications needed to control allergy symptoms
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ALVAIZ 2026

Products Affected

- ALVAIZ

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ALYFTREK 2026

Products Affected

- ALYFTREK

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

AMBRISENTAN 2026

Products Affected

- *ambrisentan*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Pulmonary Arterial Hypertension (PAH) (Initial): (1) Documentation of a diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV. (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography. (3) Documentation of all the following: (a) Mean pulmonary arterial pressure is greater than 20 mm Hg. (b) Pulmonary vascular resistance (PVR) is greater than 2.0 Woods Units (WU). (c) The pulmonary capillary wedge pressure or left ventricular end-diastolic pressure is 15 mm Hg or less.
Age Restrictions	
Prescriber Restrictions	(PAH): Prescribed by or in consultation with a Cardiologist or Pulmonologist.
Coverage Duration	(Initial): 6 months. (Continuation):12 months.
Other Criteria	(PAH)(Continuation): Stabilization or improvement as evaluated by a cardiologist or pulmonologist.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AMPYRA 2026

Products Affected

- AMPYRA

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ANTICHOLINERGIC HRM 2026

Products Affected

- *chlordiazepoxide-clidinium* mg
- LIBRAX
- *orphenadrine citrate er*
- *promethazine hcl oral tablet*
- *promethazine hcl rectal suppository 12.5 mg, 25*
- *promethazine-phenylephrine*
- PROMETHEGAN RECTAL SUPPOSITORY 25 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly
Age Restrictions	Apply if member is greater than or equal to 65 years
Prescriber Restrictions	
Coverage Duration	2 years
Other Criteria	Subject to additional clinical review for ESRD-related use - if applicable.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

ANTIDEPRESSANTS [SSRIS] ACH 2026

Products Affected

- PAXIL ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

APOKYN 2026

Products Affected

- APOKYN SUBCUTANEOUS SOLUTION
CARTRIDGE

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

APOMORPHINE INJECTION 2026

Products Affected

- *apomorphine hcl subcutaneous*

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

AQNEURSA 2026

Products Affected

- AQNEURSA

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

ARIKAYCE 2026

Products Affected

- ARIKAYCE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	(MAC): (1) Diagnosis of Mycobacterium avium complex (MAC) lung disease (2) Medication is being used as part of a combination antibacterial drug regimen (3) Used in members who have not achieved negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy
Age Restrictions	Member is 18 years of age or older
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist or an infectious disease specialist
Coverage Duration	Remainder of contract year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

ARMODAFINIL 2026

Products Affected

- *armodafinil*
- NUVIGIL

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Obstructive Sleep Apnea (OSA) (Initial) (1) Diagnosis of obstructive sleep apnea defined by ONE of the following: (A) 15 or more obstructive respiratory events per hour of sleep confirmed by a sleep study (unless prescriber provides justification confirming that a sleep study is not feasible) OR (B) BOTH of the following: (a) 5 or more obstructive respiratory events per hour of sleep confirmed by a sleep study (unless the prescriber provides justification confirming that a sleep study is not feasible) (b) ONE of the following symptoms: Unintentional sleep episodes during wakefulness, daytime sleepiness, unrefreshing sleep, fatigue, insomnia, waking up breath holding/gasping/choking, loud snoring, breathing interruptions during sleep Narcolepsy (Initial): (1) Diagnosis of narcolepsy as confirmed by sleep study (unless prescriber provides justification confirming a sleep study is not feasible) Shift Work Disorder (SWD)(Initial):(1) Diagnosis of Shift Work Disorder confirmed by ONE of the following: (A) Symptoms of excessive sleepiness or insomnia, for at least 3 months, which is associated with a work period (usually night work) that occurs during the normal sleep period OR (B) Sleep study demonstrating loss of a normal sleep-wake pattern (i.e. disturbed chronobiologic rhythmicity) (2) Confirmation that no other medical conditions or medications are causing the symptoms of excessive sleepiness or insomnia
Age Restrictions	
Prescriber Restrictions	Prescribed by or in consultation with a neurologist or sleep specialist.
Coverage Duration	12 months
Other Criteria	(OSA, Narcolepsy, SWD)(Reauth): (1) Member demonstrates positive clinical response to therapy
Indications	All Medically-accepted Indications.

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

ATTRUBY 2026

Products Affected

- ATTRUBY

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

AUSTEDO 2026

Products Affected

- AUSTEDO & 18 & 24 & 30 MG
- AUSTEDO XR
- AUSTEDO XR PATIENT TITRATION ORAL
TABLET EXTENDED RELEASE THERAPY PACK 12

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Tardive Dyskinesia (TD)(Initial): (1) Diagnosis of TD, (2) Documentation is provided of ONE of the following: (a) Persistent symptoms of tardive dyskinesia despite a trial of dose reduction, tapering or discontinuation of the offending medication, or (b) Member is not a candidate for a trial of dose reduction, tapering, or discontinuation of the offending medication. Chorea-Huntington's Disease (CHD): (1) Diagnosis of chorea associated with Huntington's disease
Age Restrictions	
Prescriber Restrictions	(CHD): Prescribed by or in consultation with a neurologist or a psychiatrist. (TD): Prescribed by or in consultation with a neurologist or a psychiatrist.
Coverage Duration	(TD)(Initial): 3 months. (TD)(Reauth): Indefinite. (CHD): Indefinite.
Other Criteria	(TD)(Reauth): Positive clinical response to therapy.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AUTHORIZED GENERICS-AUTHORIZED BRAND ALTERNATIVES 2026

Products Affected

- *dapagliflozin pro-metformin er*
- *fluticasone furoate-vilanterol inhalation aerosol powder breath activated 100-25 mcg/act, 200-25 mcg/act*
- *fluticasone-salmeterol inhalation aerosol*
- *mirabegron er*

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AUVELITY 2026

Products Affected

- AUVELITY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Major Depressive Disorder (MDD): (1) Diagnosis of major depressive disorder (MDD) (2) Inadequate response or inability to tolerate two formulary antidepressants indicated for MDD (e.g. bupropion, venlafaxine extended-release tablet or capsule, sertraline tablet, etc.)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	(All Indications): Approve if for continuation of therapy.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

BENLYSTA SC 2026

Products Affected

- BENLYSTA SUBCUTANEOUS

PA Criteria	Criteria Details
Exclusion Criteria	Member has severe active central nervous system lupus
Required Medical Information	Systemic Lupus Erythematosus (SLE)(initial): (1) Diagnosis of active, autoantibody-positive SLE confirmed by positive autoantibody test (e.g., antinuclear antibody test [ANA], antibodies to DNA [Anti-dsDNA], Anti-Smith [Anti-Sm]). (2) Member is receiving concurrent treatment with at least ONE of the following: steroids, antimalarials, immunosuppressants, nonsteroidal anti-inflammatory drugs (NSAIDS). Lupus Nephritis (LN): (1) Diagnosis of active lupus nephritis confirmed by kidney biopsy. (2) Member is receiving concurrent standard therapy (e.g. corticosteroids, immunosuppressants, azathioprine).
Age Restrictions	
Prescriber Restrictions	(SLE): Prescribed by or in consultation with a rheumatologist. (LN): Prescribed by or in consultation with a nephrologist or rheumatologist.
Coverage Duration	6 months
Other Criteria	(SLE, LN)(Reauth): (1) Member demonstrates positive clinical response to therapy
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

BIMZELX 2026

Products Affected

- BIMZELX

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

BOSENTAN 2026

Products Affected

- *bosentan oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Pulmonary Arterial Hypertension (PAH) (Initial): (1) Documentation of a diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV. (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography. (3) Documentation of all the following: (a) Mean pulmonary arterial pressure is greater than 20 mm Hg. (b) Pulmonary vascular resistance (PVR) is greater than 2.0 Woods Units (WU). (c) The pulmonary capillary wedge pressure or left ventricular end-diastolic pressure is 15 mm Hg or less.
Age Restrictions	
Prescriber Restrictions	(PAH): Prescribed by or in consultation with a Cardiologist or Pulmonologist
Coverage Duration	(Initial): 6 months. (Continuation):12 months.
Other Criteria	(PAH)(Continuation): Stabilization or improvement as evaluated by a cardiologist or pulmonologist.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

BRAND ANTIPSYCHOTICS ACH 2026

Products Affected

- LYBALVI
- ZYPREXA ORAL TABLET 2.5 MG, 20 MG, 5 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Trial of two generic formulary antipsychotics. Applies to new starts.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

BRAND HETLIOZ 2026

Products Affected

- HETLIOZ

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

BRAND SAMSCA 2026

Products Affected

- SAMSCA

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

BRUKINSA 2026

Products Affected

- BRUKINSA ORAL CAPSULE

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

BUPHENYL 2026

Products Affected

- BUPHENYL ORAL POWDER 3 GM/TSP
- BUPHENYL ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

BYLVAY 2026

Products Affected

- BYLVAY
- BYLVAY (PELLETS)

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

CAMZYOS 2026

Products Affected

- CAMZYOS

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

CAPLYTA 2026

Products Affected

- CAPLYTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Schizophrenia: (1) Diagnosis of schizophrenia (2) Inadequate response or inability to tolerate two generic antipsychotic products (e.g. aripiprazole, olanzapine, quetiapine, paliperidone). Bipolar Depression (BD): (1) Diagnosis of bipolar depression (2) Medication will be used as monotherapy or as adjunctive therapy with lithium or valproate (3) Inadequate response or inability to tolerate two medications indicated for bipolar depression (e.g. fluoxetine, Latuda (lurasidone) quetiapine, olanzapine)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	(All Indications): Approve if for continuation of therapy.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

CARBAGLU 2026

Products Affected

- CARBAGLU ORAL TABLET SOLUBLE
- *carglumic acid oral tablet soluble*

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

CAYSTON 2026

Products Affected

- CAYSTON

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Cystic Fibrosis (CF): (1) Diagnosis of CF. (2) Evidence of Pseudomonas Aeruginosa in the lungs. (3) Susceptibility results indicating that the Pseudomonas aeruginosa is sensitive to aztreonam. (4) FEV1 between 25% and 75% of predicted, (4) Member not colonized with Burkholderia cepacia.
Age Restrictions	(CF): Member is 7 years of age or older
Prescriber Restrictions	(CF): Prescribed by or in consultation with a pulmonologist OR infectious disease specialist or Specialist affiliated with a CF care center.
Coverage Duration	Remainder of contract year
Other Criteria	Reauth: (1) Evidence of Pseudomonas aeruginosa in the lungs (2) Documentation of positive clinical response to therapy (e.g. improvement in lung function demonstrated by improved FEV1)
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

CERDELGA 2026

Products Affected

- CERDELGA

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

CHOLBAM 2026

Products Affected

- CHOLBAM

PA Criteria	Criteria Details
Exclusion Criteria	(BASD, PD): Extrahepatic manifestations of bile acid synthesis disorders due to single enzyme defects or peroxisomal disorders including Zellweger spectrum disorders
Required Medical Information	Bile Acid Synthesis Disorder (BASD) (initial): (1) Diagnosis of bile acid synthesis disorder due to a single enzyme defect. Peroxisomal disorder (PD) (initial): (1) Diagnosis of peroxisomal disorder. (2) Used as adjunctive treatment. (3) Member exhibits manifestations of liver disease, steatorrhea, or complications from decreased fat soluble vitamin absorption.
Age Restrictions	
Prescriber Restrictions	(BASD, PD): Hepatologist, Gastroenterologist, Medical geneticist, other specialist that treats inborn errors of metabolism
Coverage Duration	(Initial): 3 months. (Reauth): Indefinite
Other Criteria	(BASD,PD) (Reauth): Documentation of improved liver function tests from the start of treatment.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

CIALIS 2026

Products Affected

- CIALIS ORAL TABLET 5 MG

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

CIBINQO 2026

Products Affected

- CIBINQO

PA Criteria	Criteria Details
Exclusion Criteria	(AD): Concurrent use with any other biologic immunomodulator, Janus Kinase (JAK) inhibitors, or other immunosuppressants (e.g. azathioprine, cyclosporine)
Required Medical Information	Atopic Dermatitis (AD)(Initial): (1) Diagnosis of refractory, moderate to severe AD (2) Inadequate response or inability to tolerate one systemic drug product, including biologics (e.g. Dupixent, methylprednisolone, prednisone) or member has a contraindication, intolerance, or treatment is inadvisable (3) Inadequate response or inability to tolerate ONE of the following: (a) Adbry (tralokinumab-ldrm) OR (b) Dupixent (dupilumab)
Age Restrictions	
Prescriber Restrictions	(AD): Prescribed by or in consultation with a dermatologist, allergist, immunologist.
Coverage Duration	12 months
Other Criteria	(AD)(Reauth): (1) Member demonstrates positive clinical response to therapy
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

CIMZIA 2026

Products Affected

- CIMZIA (2 SYRINGE)
- CIMZIA SUBCUTANEOUS KIT 2 X 200 MG

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
Required Medical Information	Ankylosing Spondylitis (AS)(Initial): (1) Diagnosis of AS. (2) Inadequate response or inability to tolerate two of the following: (a) secukinumab (Cosentyx), (b) Adalimumab (i.e., Adalimumab-AACF), (c) etanercept (Enbrel), (d) tofacitinib (Xeljanz/Xeljanz XR), (e) upadacitinib (Rinvoq), or documentation demonstrating that a trial may be inappropriate. Psoriatic Arthritis (PsA)(Initial): (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Adalimumab-AACF), (b) Enbrel, (c) Xeljanz/Xeljanz XR (d) Rinvoq/Rinvoq LQ, (e) Skyrizi, (f) Cosentyx, (g) Ustekinumab (i.e. Yesintek), (h) Orencia, (i) Otezla OR documentation demonstrating that a trial may be inappropriate. Plaque Psoriasis (PsO)(Initial): (1) Diagnosis of moderate to severe PsO (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Adalimumab-AACF), (b) Enbrel, (c) Skyrizi (d) Cosentyx, (e) Ustekinumab (i.e. Yesintek), (f) Otezla OR documentation demonstrating that a trial may be inappropriate. Rheumatoid Arthritis (RA): (1) Diagnosis of moderate to severe RA. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Adalimumab-AACF), (b) Enbrel, (c) Rinvoq, (d) Xeljanz/Xeljanz XR, (e) Orencia OR documentation demonstrating that a trial may be inappropriate. Crohn's Disease (CD)(Initial): (1) Diagnosis of moderate to severe CD. (2) Inadequate response or inability to tolerate two of the following: (a) Adalimumab (i.e., Adalimumab-AACF), (b) ustekinumab (i.e. Yesintek), (c) risankizumab (Skyrizi), (d) upadacitinib (Rinvoq) or documentation demonstrating that a trial may be inappropriate.
Age Restrictions	
Prescriber Restrictions	(CD): Prescribed by or in consultation with a gastroenterologist. (RA, AS, nr-axSpA, PJI): Prescribed by or in consultation with a rheumatologist. (PsA, PsO): prescribed by or in consultation with a dermatologist or rheumatologist.
Coverage Duration	12 months

PA Criteria	Criteria Details
Other Criteria	Non-Radiographic Axial Spondyloarthritis (nr-axSpA)(Initial): (1) Diagnosis of nr-axSpA (2) Inadequate response or inability to tolerate Rinvoq OR Cosentyx OR documentation demonstrating that a trial may be inappropriate (3) Inadequate response or inability to tolerate one NSAID (e.g. ibuprofen, meloxicam, naproxen). Polyarticular juvenile idiopathic arthritis (PJIA)(Initial): Diagnosis of active PJIA. (2) Inadequate response or inability to tolerate two of the following: (a) Adalimumab (i.e., Adalimumab-AACF), (b) Enbrel, (c) Xeljanz, (d) Orencia, (e) Rinvoq/Rinvoq LQ, or documentation demonstrating that a trial may be inappropriate. (AS, PsA, PsO, RA, CD, nr-axSpA, PJIA)(Reauth): (1) Member demonstrates positive clinical response to therapy
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

CINRYZE 2026

Products Affected

- CINRYZE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Part D is medically necessary when: Hereditary Angioedema (HAE)(Initial): (1) Diagnosis of hereditary angioedema (HAE) (2) For prophylaxis against HAE attacks. (3) Requested drug will not be used in combination with other products indicated for HAE prophylaxis.
Age Restrictions	
Prescriber Restrictions	(HAE): Prescribed by or in consultation with an allergist, immunologist, pulmonologist
Coverage Duration	12 months
Other Criteria	Subject to Part B vs Part D review. (HAE) (Reauth): Member demonstrates positive clinical response to therapy
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

COBENFY 2026

Products Affected

- COBENFY
- COBENFY STARTER PACK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Schizophrenia: (1) Diagnosis of schizophrenia (2) Inadequate response or inability to tolerate TWO of the following atypical antipsychotic agents: aripiprazole, asenapine, olanzapine, paliperidone, quetiapine IR/ER, risperidone, ziprasidone
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	(Schizophrenia): Indefinite
Other Criteria	(All Indications): Approve if for continuation of therapy.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

COMBINATION NSAID PRODUCTS 2026

Products Affected

- *ibuprofen-famotidine*
- *naproxen-esomeprazole mg*

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

CORLANOR 2026

Products Affected

- CORLANOR

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

COSENTYX SQ 2026

Products Affected

- COSENTYX (300 MG DOSE)
- COSENTYX SENSOREADY (300 MG)
- COSENTYX SUBCUTANEOUS SOLUTION
PREFILLED SYRINGE 75 MG/0.5ML
- COSENTYX UNOREADY

PA Criteria	Criteria Details
Exclusion Criteria	(PsA, PsO, AS, nr-axSpA, ERA, HS): Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
Required Medical Information	Psoriatic Arthritis (PsA)(Initial): (1) Diagnosis of PsA Plaque Psoriasis (PsO)(Initial): (1) Diagnosis of moderate to severe plaque psoriasis. Ankylosing Spondylitis (AS): (1) Diagnosis of AS. (2) Inadequate response or inability to tolerate one other treatment such as NSAIDs, COX2 inhibitors or methotrexate. Non-Radiographic Axial Spondyloarthritis (nr-axSpA)(Initial): (1) Diagnosis of nr-axSpA, (2) Inadequate response or inability to tolerate two NSAIDs. Active Enthesitis-related Arthritis (ERA)(Initial): (1) Diagnosis of active enthesitis-related arthritis (ERA), (2) Inadequate response or inability to tolerate methotrexate, (3) Inadequate response or inability to tolerate at least one NSAID (e.g. ibuprofen, naproxen, meloxicam, celecoxib) Hidradenitis Suppurativa (HS)(Initial): (1) Diagnosis of HS.
Age Restrictions	
Prescriber Restrictions	(PsO, HS): Prescribed by or in consultation with a dermatologist. (PsA): Prescribed by or in consultation with a rheumatologist or dermatologist. (AS, nr-axSpA, ERA): Prescribed by or in consultation with a rheumatologist.
Coverage Duration	12 months
Other Criteria	(PsA, PsO, AS, nr-axSpA, ERA, HS)(Reauth): (1) Member demonstrates positive clinical response to therapy
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

CRENESSITY 2026

Products Affected

- CRENESSITY

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

CRESEMBA [ORAL] 2026

Products Affected

- CRESEMBA ORAL

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Invasive Aspergillosis (IA): (1) For use in the treatment of invasive aspergillosis after inadequate response or inability to tolerate Voriconazole (oral Vfend). Mucormycosis (MC): (1) Diagnosis of invasive mucormycosis
Age Restrictions	(IA, MC): Member is 6 years of age or older
Prescriber Restrictions	Prescribed by or in consultation with an infectious disease specialist, oncologist, OR prescribed as part of chemotherapy prophylaxis protocol
Coverage Duration	Remainder of contract year
Other Criteria	Subject to additional clinical review for ESRD-related use - if applicable.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

CREXONT 2026

Products Affected

- CREXONT

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

CYSTEAMINE PRODUCTS 2026

Products Affected

- CYSTADROPS
- CYSTARAN

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

DALFAMPRIDINE 2026

Products Affected

- *dalfampridine er*

PA Criteria	Criteria Details
Exclusion Criteria	(Initial): Member has history of seizure or moderate to severe renal impairment (CrCL less than or equal to 50 mL/min)
Required Medical Information	Multiple Sclerosis (MS) (Initial): (1) Diagnosis of multiple sclerosis. (2) Confirmation that member has difficulty walking. (3) One of the following: (a) Member has expanded disability status scale (EDSS) score of less than or equal to 7 (b) Member is not restricted to using a wheelchair (if EDSS is not measured)
Age Restrictions	
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	Remainder of contract year
Other Criteria	(MS) (Reauth): Documentation of positive clinical response as evidenced by improvement in walking speed
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

DAYBUE 2026

Products Affected

- DAYBUE

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

DAYVIGO 2026

Products Affected

- DAYVIGO

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

DEFERASIROX 2026

Products Affected

- *deferasirox granules*
- *deferasirox oral tablet*
- *deferasirox oral tablet soluble*
- EXJADE
- JADENU
- JADENU SPRINKLE

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

DEFLAZACORT 2026

Products Affected

- *deflazacort*

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

DIACOMIT 2026

Products Affected

- DIACOMIT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Dravet syndrome (DS): (1) Diagnosis of seizures associated with Dravet syndrome (DS), (2) Used in combination with clobazam, (3) Member weighs 7kg or more.
Age Restrictions	Member is 6 months of age or older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	Indefinite
Other Criteria	(All Indications): Approve if for continuation of therapy.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

DICHLORPHENAMIDE 2026

Products Affected

- KEVEYIS
- ORMALVI

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use of high dose Aspirin, severe pulmonary disease and hepatic insufficiency
Required Medical Information	Primary hyperkalemic or hypokalemic periodic paralysis (PHPP) (Initial): (1) Diagnosis of Primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants (e.g., Paramyotonia Congenita) (2) Member has ONE of the following: (a) a positive genetic panel for periodic paralysis or (b) positive test results for periodic paralysis to one of the following tests: (i) EMG/nerve conduction studies, (ii) Long exercise test, (iii) Muscle biopsy, or (iv) Muscle MRI.
Age Restrictions	
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	(Initial): 3 months (Reauth):12 months
Other Criteria	(PHPP)(Reauth): Member has had a positive clinical response to therapy
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

DICLOFENAC 3% PRODUCTS 2026

Products Affected

- *diclofenac sodium external gel 3 %*

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

DICLOFENAC EPOLAMINE 2026

Products Affected

- *diclofenac epolamine external*
- FLECTOR EXTERNAL
- LICART EXTERNAL

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

DOJOLVI 2026

Products Affected

- DOJOLVI

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

DOPTELET 2026

Products Affected

- DOPTELET ORAL TABLET 20 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Chronic Liver Disease (CLD): (1) Diagnosis of Chronic Liver Disease (CLD) (2) Baseline platelet count less than 50,000/mcL. Member is scheduled to undergo a procedure. Chronic Immune Thrombocytopenia (ITP)(Initial): (1) Baseline platelet count less than 30,000/mcL. (2) Inadequate response or inability to tolerate one of the following: (a) corticosteroids (b) immunoglobulins (c) splenectomy (d) Rituxan (rituximab)
Age Restrictions	
Prescriber Restrictions	(ITP): Prescribed by or in consultation with hematologist/oncologist
Coverage Duration	(CLD): 1 month. (ITP): 12 months
Other Criteria	(ITP)(Continuation): (1) Positive clinical response to therapy as evidenced by an increase in platelet count to a level sufficient to avoid clinically important bleeding.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

DUPIXENT 2026

Products Affected

- DUPIXENT SUBCUTANEOUS SOLUTION AUTO-INJECTOR MG/2ML
- DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 200 MG/1.14ML, 300

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

DUVYZAT 2026

Products Affected

- DUVYZAT

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

EBGLYSS 2026

Products Affected

- EBGLYSS

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

EGRIFTA 2026

Products Affected

- EGRIFTA SV

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

EMFLAZA 2026

Products Affected

- EMFLAZA

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

EMGALITY 2026

Products Affected

- EMGALITY
- EMGALITY (300 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

EMPAVELI 2026

Products Affected

- EMPAVELI

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

EMSAM 2026

Products Affected

- EMSAM

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Major depressive disorder (MDD): (1) Diagnosis of major depressive disorder. (2) Inadequate response or inability to tolerate ONE SSRI or SNRI. (3) 4-5 half-lives (approximately 1 week) has elapsed after discontinuation of antidepressants without long half-lives OR at least 5 weeks has elapsed after discontinuation with antidepressants with long half-lives (e.g. fluoxetine).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	(All Indications): Approve if for continuation of therapy.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ENBREL 2026

Products Affected

- ENBREL MINI
- ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML
- ENBREL SUBCUTANEOUS SOLUTION PREFILLED
- SYRINGE
- ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	(RA, PsA, PJIA, PsO, AS): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
Required Medical Information	Rheumatoid Arthritis (RA)(Initial): (1) Diagnosis of moderate to severe RA. (2) Inadequate response or inability to tolerate ONE DMARD: (e.g. Methotrexate, Hydroxychloroquine, Leflunomide, Azathioprine, Sulfasalazine). Psoriatic Arthritis (PsA)(Initial): (1) Diagnosis of PsA. Polyarticular Juvenile Idiopathic Arthritis (PJIA): (1) Diagnosis of moderate to severe PJIA, (2) Inadequate response or inability to tolerate ONE of the following: Methotrexate, Leflunomide, Sulfasalazine. Plaque Psoriasis (PsO) (Initial): (1) Diagnosis of moderate to severe chronic PsO. Ankylosing Spondylitis (AS): (1) Diagnosis of AS, (2) Inadequate response or inability to tolerate one other treatment such as NSAIDs, COX2 inhibitors or methotrexate.
Age Restrictions	
Prescriber Restrictions	(RA, PJIA, AS): Prescribed by or in consultation with a rheumatologist. (PsA): Prescribed by or in consultation with a rheumatologist or dermatologist. (PsO): Prescribed by or in consultation with a dermatologist.
Coverage Duration	12 months
Other Criteria	(RA, PsA, PJIA, PsO, AS)(Reauth): (1) Member demonstrates positive clinical response to therapy
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ENDARI 2026

Products Affected

- ENDARI
- *l-glutamine oral packet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Sickle Cell Disease (SCD)(Initial): (1) One of the following: (a) Member is using Endari with concurrent hydroxyurea therapy, OR (b) Member has an inadequate response or inability to tolerate hydroxyurea. (2) Member has had 2 or more painful sickle cell crises within the past 12 months. (3) Used to reduce acute complications of sickle cell disease
Age Restrictions	
Prescriber Restrictions	(SCD): Prescribed by or in consultation with a hematologist, oncologist, or sickle cell disease management specialist.
Coverage Duration	12 months
Other Criteria	(SCD)(Reauth): Documentation of positive clinical response to therapy (e.g. reduction in the number of sickle cell crises)
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ENSPRYNG 2026

Products Affected

- ENSPRYNG

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

ENTYVIO SQ 2026

Products Affected

- ENTYVIO PEN

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
Required Medical Information	Ulcerative Colitis (UC)(Initial): (1) Diagnosis of moderately to severely active Ulcerative Colitis (2) One of the following: (A) Inadequate response or inability to tolerate two of the following: (a) Adalimumab (i.e. Adalimumab-AACF), (b) ustekinumab (i.e. Yesintek), (c) upadacitinib (Rinvoq), (d) tofacitinib (Xeljanz/Xeljanz XR), (e) risankizumab (Skyrizi) OR documentation demonstrating that a trial may be inappropriate. (B) One of the following: (a) Medication will be used as a maintenance dose following two doses of Entyvio IV for induction (b) Member is currently established on Entyvio IV. Crohn's Disease (CD)(Initial): (1) Diagnosis of moderately to severely active CD (2) One of the following: (A) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Adalimumab-AACF), (b)Ustekinumab (i.e. Yesintek), (c) Skyrizi, (d) Rinvoq or documentation demonstrating that a trial may be inappropriate. (B) One of the following: (a) Medication will be used as a maintenance dose following two doses of Entyvio IV for induction (b) Member is currently established on Entyvio IV.
Age Restrictions	
Prescriber Restrictions	(UC, CD): Prescribed by or in consultation with a gastroenterologist
Coverage Duration	12 months
Other Criteria	(UC,CD)(Reauth): (1) Member demonstrates positive clinical response to therapy
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

EPIDIOLEX 2026

Products Affected

- EPIDIOLEX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Dravet Syndrome (DS): (1) Inadequate response or inability to tolerate ONE of the following: (a) clobazam (b) valproic acid or (c) topiramate. (2) Baseline CBC, serum transaminases and total bilirubin prior to initiating therapy. (3) Concurrent use with additional anti-epileptic(s). Lennox-Gastaut Syndrome (LGS): (1) Inadequate response or inability to tolerate ONE of the following: (a) clobazam (b) valproic acid, or (c) topiramate. (2) Baseline CBC, serum transaminases and total bilirubin prior to initiating therapy. (3) Concurrent use with additional anti-epileptic(s). Tuberous Sclerosis Complex (TSC): (1) Concurrent use with additional anti-epileptic(s). (2) Baseline CBC, serum transaminases and total bilirubin prior to initiating therapy
Age Restrictions	(DS, LGS, TCS): Member is 1 year of age or older
Prescriber Restrictions	(DS, LGS, TCS): Prescribed by or in consultation with a neurologist
Coverage Duration	Indefinite
Other Criteria	(All Indications): Approve if for continuation of therapy.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

EPSOLAY 2026

Products Affected

- EPSOLAY

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ESBRIET 2026

Products Affected

- ESBRIET
- *pirfenidone*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Idiopathic Pulmonary Fibrosis (IPF): (1) Diagnosis of IPF confirmed by high resolution CT scan or biopsy.
Age Restrictions	
Prescriber Restrictions	(IPF): Prescribed by or in consultation a pulmonologist or lung transplant specialist.
Coverage Duration	12 months
Other Criteria	(REAUTH) (IPF): BOTH of the following (1) stabilization from baseline AND (2) no elevations in AST or ALT greater than 5 times upper limit of normal or greater than 3 times upper limit of normal with signs or symptoms of severe liver damage.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

EUCRISA 2026

Products Affected

- EUCRISA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Atopic Dermatitis (AD): (1) Diagnosis of mild to moderate atopic dermatitis (2) Inadequate response or inability to tolerate at least TWO of the following in patients 2 years of age or older: (a) topical tacrolimus OR topical pimecrolimus, OR (b) generic, prescription medium potency or higher topical steroid, unless the affected area is sensitive (i.e., face, axillae, groin)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

EVEKEO 2026

Products Affected

- *amphetamine sulfate*
- EVEKEO

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

EVENITY 2026

Products Affected

- EVENITY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Part D is medically necessary for: Post Menopausal Osteoporosis (PMO): (1) Diagnosis of PMO defined as ONE of the following: (a) Bone mineral density T-score less than or equal to -2.50 OR (b) Documented history of an osteoporotic non- collision fracture [e.g. vertebral, hip, nonvertebral]) AND (2) Member is at high risk of fracture as defined by one of the following: (a) Member has risk factors for a fracture (e.g. endocrine disorders, gastrointestinal disorders, use of medications associated with low bone mass or bone loss such as corticosteroids) OR (b) Inadequate response or inability to tolerate ONE of the following: (i) bisphosphonates, (ii) hormone replacement therapy, (iii) selective-estrogen receptor modulators (SERMs), OR (iv) Denosumab (Prolia). (3) Cumulative lifetime therapy does not exceed 12 months. (4) Member does NOT have a history of myocardial infarction or stroke within the preceding year or during therapy with Evenity
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Subject to Part B vs Part D review.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

EVRYSDI 2026

Products Affected

- EVRYSDI

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

EXTENDED RELEASE METFORMIN 2026

Products Affected

- *metformin hcl er (mod)*

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

EYSUVIS 2026

Products Affected

- EYSUVIS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Dry Eye Disease (DED)(Initial): (1) Diagnosis of DED (2) Inadequate response or inability to tolerate a minimum of 14 days duration of therapy to 0.5% loteprednol suspension
Age Restrictions	
Prescriber Restrictions	(DED)(Initial, Reauth): Prescribed by or in consultation with an ophthalmologist or optometrist.
Coverage Duration	(Initial, Reauth): 14 days
Other Criteria	(DED)(Reauth): (1) Positive clinical response to therapy (e.g. improvement in dry eye symptoms).
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

FABHALTA 2026

Products Affected

- FABHALTA

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

FASENRA 2026

Products Affected

- FASENRA
- FASENRA PEN

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

FERRIPROX 2026

Products Affected

- *deferiprone*
- FERRIPROX ORAL SOLUTION
- FERRIPROX ORAL TABLET 1000 MG
- FERRIPROX TWICE-A-DAY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Transfusional Iron Overload (TIO)(initial): (1) Diagnosis of transfusional iron overload due to one of the following: (a) Thalassemia syndromes, (b) sickle cell disease, (c) other transfusion-dependent anemias. (2) Inadequate response or inability to tolerate current chelation therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	(TIO) (Reauth): (1) Member demonstrates positive clinical response to therapy (e.g., greater than or equal to 20% decline in serum ferritin levels from baseline).
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

FILSPARI 2026

Products Affected

- FILSPARI

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

FILSUEZ 2026

Products Affected

- FILSUEZ

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

FINTEPLA 2026

Products Affected

- FINTEPLA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Dravet Syndrome (DS): Inadequate response or inability to tolerate ONE of the following: (a) clobazam, (b) valproic acid, (c) divalproex sodium, (d) topiramate. Lennox-Gastaut Syndrome (LGS): (1) Diagnosis of seizures associated with Lennox-Gastaut Syndrome (LGS) (2) Inadequate response or inability to tolerate ONE of the following: valproic acid, lamotrigine, topiramate, felbamate, clobazam.
Age Restrictions	(DS, LGS): Member is 2 years of age or older.
Prescriber Restrictions	(DS, LGS): Prescribed by or in consultation with a neurologist.
Coverage Duration	Indefinite.
Other Criteria	(All Indications): Approve if for continuation of therapy.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

FIRDAPSE 2026

Products Affected

- FIRDAPSE

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

GALAFOLD 2026

Products Affected

- GALAFOLD

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Fabry Disease (FD)(Initial): (1) Diagnosis of Fabry disease. (2) Member has amenable galactosidase alpha gene (GLA) variant based on in vitro assay data (3) Will not be used in combination with enzyme replacement therapy for FD (e.g. agalsidase beta or pegunigalsidase alfa)
Age Restrictions	
Prescriber Restrictions	(FD)(Initial, Reauth): Prescribed by or in consultation with a clinical genetics specialist OR a nephrologist
Coverage Duration	12 months
Other Criteria	(FD)(Reauth): (1) Positive clinical response to therapy (2) Will not be used in combination with enzyme replacement therapy for FD (e.g. agalsidase beta or pegunigalsidase alfa)
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

GATTEX 2026

Products Affected

- GATTEX

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

GENERIC LIDOCAINE TRANSDERMAL PATCH 2026

Products Affected

- *lidocaine external patch 5 %*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Post-Herpetic Neuralgia (PHN): (1) Diagnosis of post-herpetic neuralgia. Diabetic Peripheral Neuropathy (DPN): (1) Diagnosis of diabetic peripheral neuropathy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

GENERIC SODIUM PHENYLBUTYRATE 2026

Products Affected

- *sodium phenylbutyrate oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	Acute hyperammonemia. N-acetyl glutamate synthase (NAGS) deficiency
Required Medical Information	Urea Cycle Disorder (UCD): (1) Diagnosis of urea cycle disorder involving deficiencies of carbamoyl phosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AAS) confirmed via enzymatic, biochemical, or genetic testing. (2) Inadequate response to one of the following: Dietary protein restriction or Amino acid supplementation
Age Restrictions	
Prescriber Restrictions	(UCD): Prescribed by or in consultation with a specialist focused on the treatment of metabolic disorders
Coverage Duration	Initial: 6 months Reauth: 12 months
Other Criteria	(Reauth) (1) Documentation of positive clinical response to therapy (e.g. plasma ammonia or amino acid levels within normal limits) (2) Will be used concomitantly with dietary protein restriction and, in some cases, dietary supplements.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

GOCOVRI 2026

Products Affected

- GOCOVRI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Dyskinesia in Parkinson's disease (DPD): (1) Diagnosis of PD (2) Member is experiencing dyskinesia. (3) Member is receiving levodopa based therapy (4) Inadequate response or inability to tolerate amantadine immediate-release. Parkinson's Disease with OFF episodes (PD with OFF episodes): (1) Diagnosis of Parkinson's disease. (2) Concurrent use of carbidopa/levodopa containing product. (3) Member is experiencing intermittent OFF episodes. (4) Member had inadequate response or inability to tolerate ONE of the following: (a) MAO-B inhibitor (e.g. rasagiline, selegiline), (b) Dopamine agonist (e.g. pramipexole, ropinirole), (c) COMT inhibitor (e.g. entacapone).
Age Restrictions	
Prescriber Restrictions	(DPD, PD with OFF episodes): Prescribed by or in consultation with a neurologist
Coverage Duration	Indefinite
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

GRALISE 2026

Products Affected

- *gabapentin (once-daily)*
- GRALISE ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

GROWTH HORMONES 2026

Products Affected

- GENOTROPIN MINIQUICK SUBCUTANEOUS PREFILLED SYRINGE
- GENOTROPIN SUBCUTANEOUS CARTRIDGE
- HUMATROPE INJECTION CARTRIDGE
- NORDITROPIN FLEXPOR SUBCUTANEOUS SOLUTION PEN-INJECTOR
- NUTROPIN AQ NUSPIN 10 SUBCUTANEOUS SOLUTION PEN-INJECTOR
- NUTROPIN AQ NUSPIN 20 SUBCUTANEOUS SOLUTION PEN-INJECTOR
- NUTROPIN AQ NUSPIN 5 SUBCUTANEOUS SOLUTION PEN-INJECTOR
- OMNITROPE SUBCUTANEOUS SOLUTION CARTRIDGE
- OMNITROPE SUBCUTANEOUS SOLUTION RECONSTITUTED
- ZOMACTON

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	(1) Growth Failure in Children (GFC)(Initial): (a) Diagnosis of growth hormone deficiency confirmed by one of the following: (i) Height is documented by one of the following (utilizing age and gender growth charts related to height): (A) Height is greater than 2.0 standard deviations [SD] below midparental height (B) Height is greater than 2.25 SD below population mean (below the 1.2 percentile for age and gender) (ii) Growth velocity is greater than 2 SD below mean for age and gender (iii) Delayed skeletal maturation of greater than 2 SD below mean for age and gender (e.g., delayed is greater than 2 years compared with chronological age), (b) documentation of bone age, (c) abnormal response from provocative testing, such as insulin-induced hypoglycemia test, levodopa, or clonidine. (2) Small for Gestational Age (SGA)(Initial): (A) Diagnosis of SGA, (B) Clinical documentation of no catch-up growth by 2 to 4 years of age. (3) Growth Failure Associated with Chronic Kidney Disease (GF-CKD) (Initial), (4) Growth failure associated with Noonan Syndrome, Prader-Willi Syndrome, Turner Syndrome or short stature homeobox-containing gene (SHOX) deficiency (Initial), (5) Diagnostically confirmed Growth Hormone Deficiency in adults (GHDA)(Initial), OR (6) Idiopathic Short Stature (ISS)(Initial): (A) Diagnosis of ISS defined by height standard deviation score (SDS) less than or equal to 2.25, (B) Documentation of growth velocity less than 25th percentile for bone age.
Age Restrictions	
Prescriber Restrictions	(All Other Indications)(Initial): Prescribed by or in consultation with an endocrinologist. (GF-CKD)(Initial) : Prescribed by or in consultation with an endocrinologist or nephrologist
Coverage Duration	(Initial, Continuation): 12 months

PA Criteria	Criteria Details
Other Criteria	(GHDA)(Continuation): Annual clinical re-evaluation by the treating endocrinologist. (GFC)(Continuation): (1) Annual clinical re-evaluation by the treating endocrinologist (SGA, ISS)(Continuation): (1) Increase in growth velocity from baseline, (2) Annual clinical re-evaluation by the treating endocrinologist. (GF-CKD)(Continuation): (1) No history of renal transplant, (2) Annual clinical re-evaluation by the treating endocrinologist. (Growth Failure Associated with Noonan Syndrome, Prader-Willi Syndrome, Turner Syndrome or Short Stature Homeobox-Containing Gene (SHOX) Deficiency)(Continuation): (1) Annual clinical re-evaluation by the treating endocrinologist.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

HAEGARDA 2026

Products Affected

- HAEGARDA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Hereditary Angioedema (HAE) (Initial): (1) Diagnosis of HAE, (2) For prophylaxis against HAE attacks. (3) Requested drug will not be used in combination with other products indicated for HAE prophylaxis.
Age Restrictions	
Prescriber Restrictions	(HAE): Prescribed by or in consultation with an allergist, immunologist, pulmonologist
Coverage Duration	12 months
Other Criteria	(HAE)(Reauth): Member demonstrates positive clinical response to therapy
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

HETLIOZ LQ 2026

Products Affected

- HETLIOZ LQ

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

HIGH DOSE OPIOIDS 2026

Products Affected

- BELBUCA BUCCAL FILM 300 MCG, 450 MCG, 600 MCG, 750 MCG, 900 MCG
- *fentanyl transdermal patch 72 hour 100 mcg/hr, 25 mcg/hr, 37.5 mcg/hr, 50 mcg/hr, 62.5 mcg/hr, 75 mcg/hr, 87.5 mcg/hr*
- *hydrocodone bitartrate er oral tablet er 24 hour abuse-deterrent*
- *hydromorphone hcl er oral tablet extended release 24 hour*
- HYSINGLA ER ORAL TABLET ER 24 HOUR ABUSE-DETERRENT 100 MG
- *levorphanol tartrate oral tablet 3 mg*
- *methadone hcl oral solution*
- *methadone hcl oral tablet*
- *morphine sulfate er beads oral capsule extended release 24 hour 120 mg*
- *morphine sulfate er oral capsule extended release 24 hour 100 mg, 60 mg, 80 mg*
- *morphine sulfate er oral tablet extended release 100 mg, 200 mg, 60 mg*
- MS CONTIN ORAL TABLET EXTENDED RELEASE 60 MG
- NUCYNTA ER
- NUCYNTA ORAL TABLET 100 MG, 75 MG
- *oxycodone hcl oral tablet abuse-deterrent*
- OXYCONTIN ORAL TABLET ER 12 HOUR ABUSE-DETERRENT
- *oxymorphone hcl er oral tablet extended release 12 hour 20 mg, 30 mg*
- *oxymorphone hcl er oral tablet extended release 12 hour 40 mg*
- *oxymorphone hcl oral tablet 10 mg*
- ROXYBOND
- XTAMPZA ER

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	NEW TO HIGH DOSE OPIOID THERAPY : ONE of the following (A) pain associated with cancer, (B) chronic non-cancer pain and BOTH of the following (1) member is opioid tolerant (e.g. at least one week where total daily dose is at least one of the following: 30mg of oxycodone, 60mg of oral morphine, 8mg of oral hydromorphone, 25mg of oral oxymorphone or an equianalgesic dose of another opioid) AND (2) the member has been evaluated for non-opioid prescription pharmacologic treatment prior to initiation of high dose opioid therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year

PA Criteria	Criteria Details
Other Criteria	Subject to additional clinical review for ESRD-related use - if applicable. CONTINUING HIGH DOSE OPIOID THERAPY (morphine equivalent dose 90mg per day or greater): ONE of the following (1) pain associated with cancer OR (2) chronic non-cancer pain and ALL (a) member's pain has been assessed within the last 6 months AND (b) member has clinically meaningful improvement in pain and functioning that outweighs risks to patient safety AND (c) member is not being treated for substance abuse
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

HORIZANT 2026

Products Affected

- HORIZANT ORAL TABLET EXTENDED RELEASE

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

HRM 2026

Products Affected

- ALLZITAL
- ASCOMP-CODEINE
- *butalbital-acetaminophen oral capsule*
- *butalbital-acetaminophen oral tablet 50-300 mg, 50-325 mg*
- *butalbital-apap-caff-cod*
- *butalbital-apap-caffeine oral capsule*
- *butalbital-apap-caffeine oral tablet 50-325-40 mg*
- *butalbital-asa-caff-codeine*
- *butalbital-aspirin-caffeine oral capsule*
- *carbinoxamine maleate oral solution*
- *carbinoxamine maleate oral tablet*
- *chlorzoxazone oral*
- *clemastine fumarate oral syrup*
- *clemastine fumarate oral tablet 2.68 mg*
- DEMEROL INJECTION SOLUTION 25 MG/ML, 50 MG/ML
- *dipyridamole oral*
- FIORICET ORAL CAPSULE
- FIORICET/CODEINE ORAL CAPSULE 50-300-40-30 MG
- INDOCIN ORAL
- INDOCIN RECTAL
- *indomethacin oral suspension*
- *indomethacin rectal suppository 50 mg*
- *meperidine hcl injection solution 100 mg/ml, 25 mg/ml, 50 mg/ml*
- *meperidine hcl oral solution*
- *meperidine hcl oral tablet 50 mg*
- *meprobamate*
- *metaxalone oral tablet 400 mg, 800 mg*
- *pentazocine-naloxone hcl*
- *promethazine hcl oral solution 6.25 mg/5ml*
- RYVENT
- TENCON ORAL TABLET 50-325 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly
Age Restrictions	Apply if member is greater than or equal to 65 years
Prescriber Restrictions	
Coverage Duration	2 years
Other Criteria	Subject to additional clinical review for ESRD-related use - if applicable.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

HRM CYCLOBENZAPRINE 2026

Products Affected

- AMRIX
- *cyclobenzaprine hcl er*
- *cyclobenzaprine hcl oral*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Acute Muscle Spasms (AMS): (1) Diagnosis of Acute Muscle Spasms (AMS);(2) Prescriber attestation that drug will be used only for short periods. All Indications: Risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly.
Age Restrictions	Apply if member is greater than or equal to 65 years
Prescriber Restrictions	
Coverage Duration	AMS: 1 year. All other indications: 2 years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

HRM ESTROGENS 2026

Products Affected

- ABIGALE LO
- ACTIVELLA ORAL TABLET 1-0.5 MG
- ANGELIQ
- BIJUVA
- CLIMARA
- CLIMARA PRO
- DIVIGEL
- DOTTI
- ELESTRIN
- *estradiol transdermal*
- *estradiol-norethindrone acet*
- EVAMIST
- FYAVOLV
- JINTELI
- LYLLANA
- MENOSTAR
- MIMVEY
- MINIVELLE
- *norethindrone-eth estradiol*
- PREMARIN ORAL
- VIVELLE-DOT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	ONE of the following: (1) Inadequate response or inability to tolerate vaginal estrogen preparations (e.g. vaginal tablets or cream, etc.) OR (2) Risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly
Age Restrictions	Apply if member is greater than or equal to 65 years
Prescriber Restrictions	
Coverage Duration	2 years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

HRM KETOROLAC 2026

Products Affected

- *ketorolac tromethamine oral*
- SPRIX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	ONE of the following: (1) Inadequate response or inability to tolerate TWO alternative NSAIDs such as meloxicam, naproxen, celecoxib, ibuprofen, etc. OR (2) Risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly
Age Restrictions	Apply if member is greater than or equal to 65 years
Prescriber Restrictions	
Coverage Duration	One Month
Other Criteria	Subject to additional clinical review for ESRD-related use - if applicable.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

HRM NON BENZODIAZEPINE HYPNOTICS 2026

Products Affected

- AMBIEN CR ORAL TABLET EXTENDED RELEASE 12.5 MG
- AMBIEN ORAL TABLET 10 MG
- EDLUAR SUBLINGUAL TABLET SUBLINGUAL 10 MG
- *eszopiclone oral tablet 3 mg*
- LUNESTA ORAL TABLET 3 MG
- *zolpidem tartrate er oral tablet extended release 12.5 mg*
- *zolpidem tartrate oral capsule*
- *zolpidem tartrate oral tablet 10 mg*
- *zolpidem tartrate sublingual tablet sublingual 3.5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	(Initial): Risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly
Age Restrictions	Apply if member is greater than or equal to 65 years
Prescriber Restrictions	
Coverage Duration	(Initial): 3 months. (Reauth): 2 years
Other Criteria	(Reauth): Prescriber is aware of the risk versus benefit of using the medication chronically (greater than 90 days)
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

HRM NORGESIC 2026

Products Affected

- NORGESIC
- *norgesic forte*
- *orphenadrine-aspirin-caffeine oral tablet 25-385-30 mg*

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

HRM SHORT TERM SKELETAL MUSCLE RELAXANTS 2026

Products Affected

- *carisoprodol oral*
- SOMA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Acute Muscle Spasms (AMS): (1) Diagnosis of Acute Muscle Spasms (AMS):(2) Prescriber attestation that drug will be used only for short periods. All Indications: Risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly.
Age Restrictions	Apply if member is greater than or equal to 65 years
Prescriber Restrictions	
Coverage Duration	(AMS): 1 year. (All other indications): 2 years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

HYFTOR 2026

Products Affected

- HYFTOR

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

ILUMYA 2026

Products Affected

- ILUMYA

PA Criteria	Criteria Details
Exclusion Criteria	(PsO): Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
Required Medical Information	Plaque Psoriasis (PsO)(Initial): (1) Diagnosis of moderate to severe PsO. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. adalimumab-AACF), (b) Enbrel, (c) Skyrizi, (d) Cosentyx, (e) Ustekinumab (i.e. Yesintek), (f) Otezla OR documentation demonstrating that a trial may be inappropriate.
Age Restrictions	
Prescriber Restrictions	(PsO): Prescribed by or in consultation with a dermatologist
Coverage Duration	12 months
Other Criteria	Subject to Part B vs Part D review. (PsO)(Reauth): (1) Member demonstrates positive clinical response to therapy
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

INBRIJA 2026

Products Affected

- INBRIJA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Parkinson's Disease (PD): (1) Diagnosis of Parkinson's disease. (2) concurrent use of carbidopa/levodopa containing product, (3) Member is experiencing intermittent OFF episodes, (4) member had inadequate response or inability to tolerate ONE of the following: (a) MAO-B inhibitor (e.g. rasagiline, selegiline), (b) Dopamine agonist (e.g. pramipexole, ropinirole), (c) COMT inhibitor (e.g. entacapone)
Age Restrictions	
Prescriber Restrictions	(PD): Prescribed by or in consultation with a neurologist
Coverage Duration	Indefinite
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

INCRELEX 2026

Products Affected

- INCRELEX

PA Criteria	Criteria Details
Exclusion Criteria	(GHGD, PIGF-1D) (Initial and Continuation): Known or suspected malignancy, closed epiphyses, concurrent GH therapy
Required Medical Information	Growth Hormone Gene Deletion (GHGD): (Initial) (1) Diagnosis of growth hormone gene deletion who have developed neutralizing antibodies to growth hormone. Severe Primary IGF-1 Deficiency (PIGF-1D): (Initial) (1) Diagnosis of Severe primary IGF-1 deficiency AND (2) height standard deviation score less than or equal to -3.0 AND (3) basal IGF-1 standard deviation score less than or equal to -3.0 AND normal or elevated growth hormone.
Age Restrictions	(GHGD, PIGF-1D): Member is 2 years of age or older
Prescriber Restrictions	(GHGD, PIGF-1D): Prescribed by or in consultation with an endocrinologist
Coverage Duration	12 months
Other Criteria	(GHGD, PIGF-1D)(CONTINUATION): (1) Documentation of increase in growth velocity from baseline AND (2) Annual clinical re-evaluation by an endocrinologist AND (3) BOTH of the following: (a) Expected adult height is not obtained (b) documentation of expected adult height goal
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

INGREZZA 2026

Products Affected

- INGREZZA

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

INHALED TOBRAMYCIN 2026

Products Affected

- TOBI PODHALER

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Cystic Fibrosis (CF): (1) Diagnosis of cystic fibrosis AND (2) evidence of Pseudomonas aeruginosa in the lungs (3) FEV1 between 25% and 75% of predicted, (4) Member not colonized with Burkholderia cepacia.
Age Restrictions	(CF): Member is 6 years of age or older
Prescriber Restrictions	(CF): Prescribed by or in consultation with a pulmonologist, infectious disease specialist or Specialist affiliated with a CF care center.
Coverage Duration	Remainder of contract year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

INJECTABLE METHOTREXATE 2026

Products Affected

- RASUVO SUBCUTANEOUS SOLUTION AUTO-INJECTOR 10 MG/0.2ML, 12.5 MG/0.25ML, 15 MG/0.3ML, 17.5 MG/0.35ML, 20 MG/0.4ML, 22.5 MG/0.45ML, 25 MG/0.5ML, 30 MG/0.6ML, 7.5 MG/0.15ML

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Rheumatoid arthritis (RA) (Initial): (1) Diagnosis of severe, active rheumatoid arthritis (RA), (2) Inadequate response or inability to tolerate oral methotrexate. Psoriatic Arthritis (PsA)(Initial): (1) Diagnosis of PsA, (2) Inadequate response or inability to tolerate oral methotrexate. Polyarticular juvenile idiopathic arthritis (PJIA)(Initial): (1) Diagnosis of PJIA, (2) Inadequate response or inability to tolerate oral methotrexate. Psoriasis (Initial): (1) Diagnosis of severe psoriasis, (2) Inadequate response to BOTH of the following: (a) oral methotrexate AND (b) topical steroids (e.g. clobetasol propionate cream/ointment, betamethasone cream/ointment, etc.).
Age Restrictions	
Prescriber Restrictions	(RA, PJIA): Recommended by rheumatologist. (PSA): Recommended by a rheumatologist or dermatologist. (Psoriasis): Recommended by dermatologist
Coverage Duration	12 months
Other Criteria	(RA, PJIA, PSA, Psoriasis) (Reauth): (1) Member demonstrates positive clinical response to therapy
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

INSULIN GLARGINE 2026

Products Affected

- *insulin glargine max solostar*
- *insulin glargine solostar subcutaneous solution pen-injector 300 unit/ml*

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

INTRAVENOUS IMMUNE GLOBULINS (IVIG) 2026

Products Affected

- BIVIGAM INTRAVENOUS SOLUTION 5 GM/50ML GM/50ML
- GAMMAGARD INJECTION SOLUTION 2.5 GM/25ML
- GAMMAGARD S/D LESS IGA
- GAMMAKED INJECTION SOLUTION 1 GM/10ML
- GAMMAPLEX INTRAVENOUS SOLUTION 10 GM/100ML, 10 GM/200ML, 20 GM/200ML, 5 GM/200ML
- GAMUNEX-C INJECTION SOLUTION 1 GM/10ML
- OCTAGAM INTRAVENOUS SOLUTION 1 GM/20ML, 2 GM/20ML
- PANZYGA
- PRIVIGEN INTRAVENOUS SOLUTION 20 GM/200ML

PA Criteria	Criteria Details
Exclusion Criteria	(Initial): History of hypersensitivity (including anaphylaxis or severe systemic reaction) to immune globulin or any component of the preparation.
Required Medical Information	Part D is medically necessary when ONE of the following is present: (1) Autoimmune mucocutaneous blistering disease pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, mucous membrane (cicatricial) pemphigoid, benign mucous membrane pemphigoid, epidermolysis bullosa acquisita and ONE of the following: (a) inadequate response or inability to tolerate conventional therapy (i.e. steroids, immunosuppressants) OR (b) rapidly progressive disease in conjunction with conventional therapy (i.e. steroids, immunosuppressants). (2) Acute Idiopathic Thrombocytopenia Purpura (ITP) and ONE of the following (a) management of acute bleeding (b) used to increase platelet count prior to surgical procedures (c) severe thrombocytopenia (platelets less than 20,000 per uL) or (d) high risk for intracerebral hemorrhage. (3) Chronic ITP and ALL of the following (a) inadequate response or inability to tolerate corticosteroids (b) duration of illness greater than 6 months (c) platelets persistently less than 20,000/ uL. (4) Chronic B-cell lymphocytic leukemia with IgG less than 600mg/dL and recurrent, serious bacterial infections requiring antibiotic therapy. (5) Hematopoietic stem cell transplant and IgG less than 400mg/dL. (6) HIV and all of the following (a) less than 14 years of age (b) evidence of qualitative or quantitative humoral immunologic defects and (c) current bacterial infection despite antimicrobial prophylaxis. (7) Solid organ transplant. (8) Chronic Inflammatory Demyelinating Polyneuritis confirmed by electrodiagnostic testing or nerve biopsy and an inadequate response or inability to tolerate corticosteroids. (9) Dermatomyositis or Polymyositis diagnosed by laboratory testing (antinuclear or myositis specific antibodies), biopsy, EMG, or MRI) and inadequate response or inability to tolerate steroids or immunosuppressants. (10) Guillain Barre syndrome with impaired function (i.e. unable to stand or walk without aid).
Age Restrictions	

PA Criteria	Criteria Details
Prescriber Restrictions	Prescribed by or in consultation with a physician who has specialized expertise in managing patients on immune globulin therapy (e.g. immunologist, hematologist, neurologist).
Coverage Duration	6 months
Other Criteria	Subject to Part B vs Part D review. (11) Lambert Eaton myasthenic syndrome and an inadequate response or inability to tolerate steroids, immunosuppressants, or cholinesterase inhibitors (12) Multifocal motor neuropathy diagnosed by electrodiagnostic studies. (13) Acute exacerbations of multiple sclerosis (MS) unresponsive to steroids. (14) Myasthenia gravis and an inadequate response or inability to tolerate at least 8 weeks of standard therapy (e.g. corticosteroids, azathioprine, cyclosporine, cyclophosphamide, cholinesterase inhibitors) (15) Myasthenic crisis (16) Stiff person syndrome and an inadequate response or inability to tolerate standard therapy (e.g. muscle relaxants, benzodiazepines, and gabapentin-related medications) (17) Severe, active SLE and an inadequate response or inability to tolerate steroids (18) Kawasaki disease. (19) Infections in Low-birthweight Neonates when severe hypogammaglobulinemia (IgG greater than or equal to 400 mg/dL) is present. (20) Graves? Ophthalmopathy (21) Immune mediated Necrotizing Myopathy when resistant to treatment with glucocorticoids and immunosuppressants (22) Graves disease (All Indications)(CONTINUATION): (1) Documentation of clinical improvement as appropriate to the diagnosis (e.g. clinical improvement in symptoms, Rankin score and Activities of Daily Living (ADL) scores, etc.)
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

INZIRQO 2026

Products Affected

- INZIRQO

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

IQIRVO 2026

Products Affected

- IQIRVO

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ISTURISA 2026

Products Affected

- ISTURISA ORAL TABLET 1 MG, 5 MG

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

IVABRADINE 2026

Products Affected

- *ivabradine hcl*

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

JOENJA 2026

Products Affected

- JOENJA

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

JUXTAPID 2026

Products Affected

- JUXTAPID ORAL CAPSULE 10 MG, 20 MG, 30 MG, 5 MG

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

JYNARQUE 2026

Products Affected

- JYNARQUE
- *tolvaptan*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	(Autosomal Dominant Polycystic Kidney Disease (ADPKD): (Initial): (1) Diagnosis of autosomal dominant polycystic kidney disease with risk of rapidly progressing kidney disease (2) Baseline serum transaminases and bilirubin obtained prior to initiation of therapy.
Age Restrictions	
Prescriber Restrictions	Prescribed by or in consultation with a nephrologist or kidney transplant specialist
Coverage Duration	(Initial): 3 months. (Reauth): 12 months.
Other Criteria	(ADPKD)(Reauth): (1) ONE of the following (a) decline in kidney function has slowed or (b) kidney pain has improved and (2) serum transaminase less than 3 times the upper limit of normal and (3) bilirubin less than 2 times upper limit of normal
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

KALYDECO 2026

Products Affected

- KALYDECO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Cystic Fibrosis (CF)(Initial): (1) Diagnosis of Cystic Fibrosis (2) One of the following: (a) Documentation of one mutation in the CFTR gene that is responsive to ivacaftor based on clinical and/or in vitro assay data, (b) If the member's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test
Age Restrictions	(CF): Member is 1 month of age or older for granules. Member is 6 years of age or older for tablets
Prescriber Restrictions	(CF): Prescribed by or in consultation with a pulmonologist or Specialist affiliated with a CF care center
Coverage Duration	12 months
Other Criteria	(CF)(Reauth): Member has had a positive clinical response to therapy
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

KERENDIA 2026

Products Affected

- KERENDIA ORAL TABLET 10 MG, 20 MG

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

KEVZARA 2026

Products Affected

- KEVZARA

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
Required Medical Information	Rheumatoid arthritis (RA)(Initial): (1) Diagnosis of RA. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Adalimumab-AACF), (b) etanercept (Enbrel), (c) Rinvoq, (d) Xeljanz/Xeljanz XR, (e) Orencia OR documentation demonstrating that a trial may be inappropriate. Polymyalgia Rheumatica (PMR)(Initial): (1) Diagnosis of polymyalgia rheumatica (2) Inadequate response or inability to tolerate corticosteroids (e.g. prednisone). Polyarticular Juvenile Idiopathic Arthritis (PJIA)(Initial): (1) Diagnosis of active polyarticular juvenile idiopathic arthritis (PJIA) (2) Member weighs at least 63 kg (3) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Adalimumab-AACF) (b) Enbrel, (c) Xeljanz, (d) Orencia, (e) Rinvoq/Rinvoq LQ OR documentation demonstrating that a trial may be inappropriate.
Age Restrictions	
Prescriber Restrictions	(RA, PMR, PJIA): Prescribed by or in consultation with a rheumatologist
Coverage Duration	12 months
Other Criteria	(RA, PMR, PJIA) (Reauth): (1) Member demonstrates positive clinical response to therapy as evidenced by at least one of the following: (a) Reduction in total active (swollen and tender) joint count from baseline or (b) Improvement in symptoms (e.g., pain, stiffness, inflammation) from baseline
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

KINERET 2026

Products Affected

- KINERET SUBCUTANEOUS SOLUTION
PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
Required Medical Information	Rheumatoid Arthritis (RA)(Initial): (1) Diagnosis of RA. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. adalimumab-AACF), (b) etanercept (Enbrel), (c) Rinvog, (d) Xeljanz/Xeljanz XR, (e) Orencia OR documentation demonstrating that a trial may be inappropriate. Neonatal-Onset Multisystem Inflammatory Disease (NOMID)(Initial): (1) Diagnosis of NOMID. (2) Diagnosis has been confirmed by one of the following: (a) NLRP-3 (nucleotide-binding domain, leucine rich family (NLR), pyrin domain containing 3] gene (also known as Cold-Induced Auto-inflammatory Syndrome-1 [CIAS1]) mutation (b) Evidence of active inflammation including both of the following: (i) clinical symptoms (e.g. rash, fever, arthralgia) (ii) elevated acute phase reactants (e.g. ESR, CRP). Deficiency of Interleukin-1 Receptor Antagonist (DIRA): (1) Diagnosis of DIRA.
Age Restrictions	
Prescriber Restrictions	(RA, NOMID, DIRA): Prescribed by or in consultation with a rheumatologist or pediatric specialist.
Coverage Duration	12 months
Other Criteria	(RA, NOMID, DIRA)(Reauth): (1) Member demonstrates positive clinical response to therapy
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

KLISYRI 2026

Products Affected

- KLISYRI (250 MG)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Actinic Keratoses: (1) Diagnosis of Actinic Keratoses (2) Inadequate response or inability to tolerate BOTH of the following generics: Topical fluorouracil and topical imiquimod
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	30 days
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

KORLYM 2026

Products Affected

- KORLYM
- *mifepristone oral tablet 300 mg*

PA Criteria	Criteria Details
Exclusion Criteria	Pregnancy
Required Medical Information	Hyperglycemia in members with Cushing Syndrome (HCS)(Initial): (1) Hyperglycemia secondary to hypercortisolism in adult member with endogenous Cushing syndrome, (2) member has type 2 diabetes mellitus or glucose intolerance, (3) member has failed surgery or is not a candidate for surgery.
Age Restrictions	
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist
Coverage Duration	12 months
Other Criteria	(HCS)(Reauth): Documentation of positive clinical response to therapy (e.g., improved, or stable glucose tolerance while on therapy)
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

LETAIRIS 2026

Products Affected

- LETAIRIS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Pulmonary Arterial Hypertension (PAH) (Initial): (1) Documentation of a diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV. (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography. (3) Documentation of all the following: (a) Mean pulmonary arterial pressure is greater than 20 mm Hg. (b) Pulmonary vascular resistance (PVR) is greater than 2.0 Woods Units (WU). (c) The pulmonary capillary wedge pressure or left ventricular end-diastolic pressure is 15 mm Hg or less.(4) Inadequate response or inability to tolerate generic ambrisentan
Age Restrictions	
Prescriber Restrictions	(PAH): Prescribed by or in consultation with a Cardiologist or Pulmonologist.
Coverage Duration	(Initial): 6 months. (Continuation):12 months.
Other Criteria	(PAH)(Continuation): Stabilization or improvement as evaluated by a cardiologist or pulmonologist.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

LISDEXAMFETAMINE 2026

Products Affected

- *lisdexamfetamine dimesylate*

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

LITFULO 2026

Products Affected

- LITFULO

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

LIVDELZI 2026

Products Affected

- LIVDELZI

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

LIVMARLI 2026

Products Affected

- LIVMARLI

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

LIVTENCITY 2026

Products Affected

- LIVTENCITY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Cytomegalovirus (CMV): (1) Diagnosis of cytomegalovirus (CMV) infection/disease, (2) Member is a recipient of one of the following (a) Hematopoietic stem cell transplant, (b) solid organ transplant, (3) Inadequate response to a minimum 2 weeks duration or inability to tolerate one prior therapy at an appropriately indicated dose (e.g., oral valganciclovir)(4) For pediatric members 12 years of age or older, Member weighs greater than or equal to 35kg
Age Restrictions	(CMV): Member is 12 years of age or older
Prescriber Restrictions	(CMV): Prescribed by or in consultation with a provider who specializes in one of the following areas (1) transplant, (2) infectious disease (3) Oncology
Coverage Duration	8 weeks
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

LODOCO 2026

Products Affected

- LODOCO

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

LUMRYZ 2026

Products Affected

- LUMRYZ
- LUMRYZ STARTER PACK

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

LUPKYNIS 2026

Products Affected

- LUPKYNIS

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

LYRICA CR 2026

Products Affected

- LYRICA CR
- *pregabalin er*

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

METFORMIN IR 2026

Products Affected

- *metformin hcl oral tablet 625 mg, 750 mg*

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

METHOCARBAMOL 1000MG TAB 2026

Products Affected

- *methocarbamol oral tablet 1000 mg*
- TANLOR

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

MIPLYFFA 2026

Products Affected

- MIPLYFFA

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

MODAFINIL 2026

Products Affected

- *modafinil oral*
- PROVIGIL

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Obstructive Sleep Apnea (OSA) (Initial) (1) Diagnosis of obstructive sleep apnea defined by ONE of the following: (A) 15 or more obstructive respiratory events per hour of sleep confirmed by a sleep study (unless prescriber provides justification confirming that a sleep study is not feasible) OR (B) BOTH of the following: (a) 5 or more obstructive respiratory events per hour of sleep confirmed by a sleep study (unless the prescriber provides justification confirming that a sleep study is not feasible) (b) ONE of the following symptoms: Unintentional sleep episodes during wakefulness, daytime sleepiness, unrefreshing sleep, fatigue, insomnia, waking up breath holding/gasping/choking, loud snoring, breathing interruptions during sleep Narcolepsy (Initial): (1) Diagnosis of narcolepsy as confirmed by sleep study (unless prescriber provides justification confirming a sleep study is not feasible) Shift Work Disorder (SWD)(Initial):(1) Diagnosis of Shift Work Disorder confirmed by ONE of the following: (A) Symptoms of excessive sleepiness or insomnia, for at least 3 months, which is associated with a work period (usually night work) that occurs during the normal sleep period OR (B) Sleep study demonstrating loss of a normal sleep-wake pattern (ie, disturbed chronobiologic rhythmicity) (2) Confirmation that no other medical conditions or medications are causing the symptoms of excessive sleepiness or insomnia Fatigue due to MS (off-label) (Initial): (1) Diagnosis of multiple sclerosis (MS) (2) Member is experiencing fatigue.
Age Restrictions	
Prescriber Restrictions	Prescribed by or in consultation with a neurologist or sleep specialist.
Coverage Duration	12 months
Other Criteria	(OSA, Narcolepsy, SWD)(Reauth): (1) Member demonstrates positive clinical response to therapy (MS)(Reauth): (1) Member is experiencing relief of fatigue with modafinil therapy

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

MULPLETA 2026

Products Affected

- MULPLETA

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

MYALEPT 2026

Products Affected

- MYALEPT

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

MYCAPSSA 2026

Products Affected

- MYCAPSSA

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

MYFEMBREE 2026

Products Affected

- MYFEMBREE

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

MYTESI 2026

Products Affected

- MYTESI

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

NEMLUVIO 2026

Products Affected

- NEMLUVIO

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

NEXLETOL/NEXLIZET 2026

Products Affected

- NEXLETOL
- NEXLIZET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Heterozygous Familial Hypercholesterolemia (HeFH) OR Primary hyperlipidemia (PH). (Initial): (1) One of the following: (A) Diagnosis of HeFH, OR (B) Diagnosis of Primary hyperlipidemia (2) ONE of the following: (A) LDL-C 70 mg/dL or greater after at least 8 weeks of one low, moderate or high-intensity statin therapy and member will continue to receive statin therapy at maximally tolerated dose OR (B) Inability to tolerate statin therapy as documented by one of the following: (i) member had rhabdomyolysis or symptoms with creatine kinase (CK) exceeding 10 times the upper limit of normal (ULN) or (ii) either of the following with TWO statins: myalgia (no CK elevation) or myositis (CK less than 10 times ULN or (iii) hepatotoxicity from statin use (increased AST/ALT exceeding 3 times ULN) or (iv) liver disease documented by Child Pugh A or worse OR AST/ALT exceeding 3 times ULN for at least 6 weeks. (3) One of the following: (A) Member has been receiving at least 8 weeks of ezetimibe (Zetia) therapy as adjunct to maximally tolerated statin therapy OR (B) Member has contraindication or intolerance to ezetimibe (Zetia).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	(Initial): 6 months. (Continuation): 12 months

PA Criteria	Criteria Details
Other Criteria	Established cardiovascular disease (CVD) or high risk for a CVD event but without established CVD (Initial): (1) One of the following: (A) Diagnosis of established cardiovascular disease (CVD) (e.g., coronary artery disease, symptomatic peripheral arterial disease, cerebrovascular atherosclerotic disease) OR (B) Diagnosis of a high risk for a CVD event but without established CVD [e.g., diabetes mellitus (type 1 or type 2) in females over 65 years of age or males over 60 years of age] (2) One of the following: (A) Member is statin intolerant as evidenced by an inability to tolerate at least two statins, with at least one started at the lowest starting daily dose, due to intolerable symptoms or clinically significant biomarker changes of liver function or muscle function (e.g., creatine kinase) (B) Member has a contraindication to all statins (3) ONE of the following LDL-C values within the last 120 days (A) LDL-C greater than or equal to 55 mg/dL with ASCVD OR (B) LDL-C greater than or equal to 100 mg/dL without ASCVD (4) One of the following (A) For Nexletol, ONE of the following: (i) Member has been receiving at least 12 weeks of generic ezetimibe therapy (ii) Patient has a history of contraindication, or intolerance to ezetimibe OR (B) For Nexlizet, member has been receiving at least 12 weeks of generic ezetimibe therapy (HeFH, PH) (Continuation): (1) Positive Clinical response to therapy (e.g. reduction in LDL-C levels). (CVD) (Continuation): (1) Positive Clinical response to therapy
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

NGENLA 2026

Products Affected

- NGENLA

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

NON-ORAL ANTIBIOTICS 2026

Products Affected

- DALVANCE
- NUZYRA
- SIVEXTRO
- VABOMERE
- ZEMDRI
- ZERBAXA

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

NON-ORAL CHEMO AGENTS 2026

Products Affected

- BESREMI
- TRELSTAR MIXJECT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Part D is medically necessary when ANY of the following inclusion criteria is met: (1) Drug is FDA approved for indication and regimen requested, (2) The indication and regimen is classified as Category 1 or 2A by National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium, (3) narrative text in The American Hospital Formulary Service-Drug Information (AHFS-DI) or Clinical Pharmacology Compendium is supportive for the specific condition(s) requested, (4) The Micromedex Compendium and the strength of recommendation is listed as Class I, Class IIa, or Class IIb for the specific condition(s) requested, (5) Indication is listed in Lexi-Drugs as ?off label? with evidence level A, (6) supported by Peer-Reviewed Medical Literature as defined in Chapter 15 Section 50.4.5 of the Medicare Benefit Policy Manual
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	(All Indications): Approve if for continuation of therapy. Subject to Part B vs Part D review.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

NON-PREFERRED DENOSUMAB 2026

Products Affected

- PROLIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

NON-PREFERRED GLP-1 AGONISTS 2026

Products Affected

- *exenatide*
- SOLIQUA
- VICTOZA SUBCUTANEOUS SOLUTION PEN-INJECTOR
- XULTOPHY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	(DM2)(Initial): (1) One of the following: (a) For members requiring ongoing treatment for type 2 diabetes mellitus, submission of medical records (e.g. chart notes) confirming diagnosis of type 2 diabetes mellitus (b) Submission of medical records (e.g. chart notes) confirming diagnosis of type 2 diabetes mellitus as evidenced by one of the following laboratory values (i) A1C greater than or equal to 6.5 percent (ii) Fasting plasma glucose (FPG) greater than or equal to 126 mg/dL (iii) 2-hour plasma glucose (PG) greater than or equal to 200 mg/dL during OGTT (oral glucose tolerance test) (2) Inadequate response or inability to tolerate a minimum 90 day-supply of two of the following preferred brands: Ozempic, Trulicity, Rybelsus, Mounjaro, liraglutide
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	(DM2)(Reauth): Documentation of positive clinical response to therapy
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

NON-PREFERRED HEPATITIS C AGENTS 2026

Products Affected

- SOVALDI
- VOSEVI
- ZEPATIER

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	(1) Documentation of member's Hepatitis C genotype. (2) Prescribed regimen is consistent with the current AASLD/ IDSA guidance. (3) Inability to tolerate ONE of the following when appropriate per the current AASLD/IDSA guidance: Harvoni, Epclusa, or Mavyret.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Duration will be applied consistent with AASLD/ IDSA guidance
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

NON-PREFERRED TOCILIZUMAB SQ 2026

Products Affected

- ACTEMRA ACTPEN
- ACTEMRA SUBCUTANEOUS

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

NON-PREFERRED USTEKINUMAB SQ 2026

Products Affected

- OTULFI SUBCUTANEOUS
- PYZCHIVA SUBCUTANEOUS SOLUTION
REFILLED SYRINGE
- SELARSDI SUBCUTANEOUS
- STELARA SUBCUTANEOUS SOLUTION 45
MG/0.5ML
- STELARA SUBCUTANEOUS SOLUTION
REFILLED SYRINGE
- STEQEYMA SUBCUTANEOUS
- *ustekinumab subcutaneous*
- *ustekinumab-ttwe subcutaneous*
- WEZLANA SUBCUTANEOUS

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
Required Medical Information	Part D is medically necessary when: Crohn's Disease (CD)(Initial): (1) Diagnosis of moderate to severe CD (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Adalimumab-AACF), (b) Skyrizi, (c) Rinvoq (d) Ustekinumab (i.e. Yesintek) or documentation demonstrating that a trial may be inappropriate. Ulcerative Colitis (UC)(Initial): (1) Diagnosis of moderate to severe UC. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Adalimumab-AACF), (b) Rinvoq, (c) Xeljanz/Xeljanz XR, (d) Skyrizi (e) Ustekinumab (i.e. Yesintek) OR documentation demonstrating that a trial may be inappropriate. Psoriatic arthritis (PsA)(Initial): (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Adalimumab-AACF), (b) Enbrel, (c) Xeljanz/Xeljanz XR (d) Rinvoq/Rinvoq LQ, (e) Skyrizi, (f) Cosentyx, (g) Orencia, (h) Otezla, (i) Ustekinumab (i.e. Yesintek) OR documentation demonstrating that a trial may be inappropriate. Plaque psoriasis (PsO)(Initial): Diagnosis of moderate to severe PsO. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Adalimumab-AACF), (b) Enbrel, (c) Skyrizi (d) Cosentyx, (e) Otezla, (f) Ustekinumab (i.e. Yesintek) OR documentation demonstrating that a trial may be inappropriate.
Age Restrictions	
Prescriber Restrictions	(CD, UC): prescribed by or in consultation with a Gastroenterologist. (PsO): prescribed by or in consultation with a Dermatologist. (PsA): prescribed by or in consultation with a Dermatologist or Rheumatologist
Coverage Duration	(CD, UC, PsA, PsO): 12 months
Other Criteria	(CD, UC, PsA, PsO): (Reauth): (1) Member demonstrates positive clinical response to therapy

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

NOURIANZ 2026

Products Affected

- NOURIANZ

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Parkinson's Disease (PD) (Initial): (1) Diagnosis of Parkinson's disease. (2) concurrent use of carbidopa/levodopa containing product, (3) Member is experiencing intermittent OFF episodes, (4) member had inadequate response or inability to tolerate ONE of the following: (a) MAO-B inhibitor (e.g. rasagiline, selegiline), (b) Dopamine agonist (e.g. pramipexole, ropinirole), (c) COMT inhibitor (e.g. entacapone)
Age Restrictions	
Prescriber Restrictions	Prescribed by or in consultation with a neurologist.
Coverage Duration	12 months
Other Criteria	Parkinson's Disease (PD) (Reauth): (1) Member demonstrates positive response to clinical therapy (2) concurrent use of carbidopa/levodopa containing product
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

NOXAFIL 2026

Products Affected

- NOXAFIL ORAL SUSPENSION
- *posaconazole oral*

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

NOXAFIL 300MG PAK 2026

Products Affected

- NOXAFIL ORAL PACKET

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

NUCALA 2026

Products Affected

- NUCALA

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

NUEDEXTA 2026

Products Affected

- NUEDEXTA

PA Criteria	Criteria Details
Exclusion Criteria	(PBA) 1) Concomitant use with other drugs containing quinidine, quinine, or mefloquine, (2) History of Nuedexta, quinine, mefloquine or quinidine-induced thrombocytopenia, hepatitis, bone marrow depression, or lupus-like syndrome, (3) Known hypersensitivity to dextromethorphan (e.g., rash, hives), (4) Taking monoamine oxidase inhibitors (MAOIs) (e.g., phenelzine, selegiline, tranylcypromine) or have taken MAOIs within the preceding 14 days, (5) Presence of prolonged QT interval, congenital long QT syndrome or a history suggestive of torsades de pointes, or has heart failure, (6) Receiving drugs that both prolong QT interval and are metabolized by CYP2D6 (e.g., thioridazine, pimozide), (7) Has complete atrioventricular (AV) block without implanted pacemakers, or at high risk of complete AV block]
Required Medical Information	Pseudobulbar Affect (PBA) (Initial): (1) Diagnosis of Pseudobulbar affect (2) Member has one of the following underlying conditions: (a) Amyotrophic lateral sclerosis (b) Multiple sclerosis (c) Alzheimer's disease (d) Parkinson's disease (e) Stroke (f) Traumatic brain injury
Age Restrictions	(PBA): Member is 18 years of age or older
Prescriber Restrictions	(PBA): Prescribed by or in consultation with a neurologist or psychiatrist
Coverage Duration	12 months
Other Criteria	(PBA)(Reauth): (1) Documentation of clinical benefit from ongoing therapy (e.g., decrease in laughing or crying episodes)
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

NUPLAZID 2026

Products Affected

- NUPLAZID ORAL CAPSULE
- NUPLAZID ORAL TABLET 10 MG

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

NURTEC 2026

Products Affected

- NURTEC

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

OCALIVA 2026

Products Affected

- OCALIVA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Primary biliary cholangitis (PBC): (1) Diagnosis of Primary biliary cholangitis (PBC) (2) One of the following: (a) Used in combination with ursodeoxycholic acid (e.g. Urso, Urso Forte, ursodiol), OR (b) inability to tolerate ursodeoxycholic acid (3) Member has one of the following: (a) no cirrhosis or (b) compensated cirrhosis with no evidence of portal hypertension. (4) Requested drug will not be used in combination with Livdelzi (seladelpar) or Iqirvo (elafibranor)
Age Restrictions	
Prescriber Restrictions	Prescribed by or in consultation with a hepatologist or gastroenterologist
Coverage Duration	(Initial): 6 months. (Reauth): Indefinite
Other Criteria	(PCB)(Reauth): (1) Positive clinical response to Ocaliva therapy (2) Member does not have evidence of advanced cirrhosis (i.e. cirrhosis with current or prior evidence of hepatic decompensation including encephalopathy or coagulopathy) (3) Member does not have evidence of portal hypertension (e.g., ascites, gastroesophageal varices, persistent thrombocytopenia)
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

OCTREOTIDE 2026

Products Affected

- *octreotide acetate injection solution 100 mcg/ml, 1000 mcg/ml, 200 mcg/ml, 50 mcg/ml, 500 mcg/ml* MCG/ML, 50 MCG/ML, 500 MCG/ML
- SANDOSTATIN INJECTION SOLUTION 100

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

OFEV 2026

Products Affected

- OFEV

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

OHTUVAYRE 2026

Products Affected

- OHTUVAYRE

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

OLPRUVA 2026

Products Affected

- OLPRUVA (2 GM DOSE)
- OLPRUVA (3 GM DOSE)
- OLPRUVA (4 GM DOSE)
- OLPRUVA (5 GM DOSE)
- OLPRUVA (6 GM DOSE)
- OLPRUVA (6.67 GM DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

OLUMIANT 2026

Products Affected

- OLUMIANT

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists, JAK inhibitors, or potent immunosuppressants such as azathioprine, cyclosporine
Required Medical Information	Rheumatoid arthritis (RA)(Initial): (1) Diagnosis of RA. (2) Inadequate response or inability to tolerate two of the following: (a) Adalimumab (i.e. adalimumab-AACF), (b) Enbrel (c) Rinvoq, (d) Xeljanz/Xeljanz XR, (e) Orencia OR documentation demonstrating that a trial may be inappropriate. Alopecia Areata (AA)(Initial): (1) Diagnosis of alopecia areata (2) Member has at least 50% scalp hair loss (3) Other causes of hair loss have been ruled out (e.g. androgenetic alopecia, trichotillomania, tinea capitis, psoriasis) (4) Inadequate response or inability to tolerate one previous treatment for alopecia areata (e.g. topical, intralesional, or systemic corticosteroids, topical immunotherapy)
Age Restrictions	
Prescriber Restrictions	(RA): Prescribed by or in consultation with a rheumatologist (AA): Prescribed by or in consultation with a dermatologist
Coverage Duration	12 months
Other Criteria	(RA, Alopecia Areata)(Reauth): (1) Member demonstrates positive clinical response to therapy
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

OMVOH SQ 2026

Products Affected

- OMVOH (300 MG DOSE)
- OMVOH SUBCUTANEOUS

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ONGENTYS 2026

Products Affected

- ONGENTYS

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ONYCHOMYCOSIS AGENTS 2026

Products Affected

- JUBLIA
- *tavaborole*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Onychomycosis: (1) Diagnosis of onychomycosis of the toenail(s) due to <i>Trichophyton rubrum</i> and <i>Trichophyton mentagrophytes</i> . (2) Diagnosis confirmed by one of the following: (a) positive potassium hydroxide (KOH) preparation, (b) culture, or (c) histology. (3) Condition is causing debility or a disruption in member's activities of daily living. (4) Inadequate response or inability to tolerate BOTH of the following: (a) oral generic terbinafine, AND (b) oral generic itraconazole OR topical generic ciclopirox.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ONYDA XR 2026

Products Affected

- ONYDA XR

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

OPIPZA 2026

Products Affected

- OPIPZA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Schizophrenia: (1) Diagnosis of treatment of schizophrenia (2) Inadequate response or inability to tolerate aripiprazole and an additional generic formulary antipsychotic product. Major depressive disorder (MDD): (1) Diagnosis of adjunctive treatment of MDD (2) Inadequate response or inability to tolerate aripiprazole and quetiapine. Autistic disorder: (1) Diagnosis of irritability associated with autistic disorder (2) Inadequate response or inability to tolerate aripiprazole and risperidone. Tourette?s disorder: (1) Diagnosis of treatment of Tourette?s disorder (2) Inadequate response or inability to tolerate aripiprazole.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	(All Indications): Approve if for continuation of therapy.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

OPSYNVI 2026

Products Affected

- OPSYNVI

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

OPZELURA 2026

Products Affected

- OPZELURA

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ORAL ANTIBIOTICS 2026

Products Affected

- NUZYRA
- SIVEXTRO

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ORAL CHEMO AGENTS 2026

Products Affected

- *abiraterone acetate*
- ABIRTEGA
- AFINITOR
- AFINITOR DISPERZ
- AKEEGA
- ALECENSA
- ALUNBRIG
- AUGTYRO
- AVMAPKI FAKZYNJA CO-PACK
- AYVAKIT
- BALVERSA
- *bexarotene*
- BOSULIF
- BRAFTOVI ORAL CAPSULE 75 MG
- CABOMETYX
- CALQUENCE ORAL TABLET
- CAPRELSA
- COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MG
- COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MG
- COMETRIQ (60 MG DAILY DOSE)
- COPIKTRA
- COTELLIC
- DANZITEN
- *dasatinib*
- DAURISMO
- ERIVEDGE
- ERLEADA
- *erlotinib hcl*
- *everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg*
- *everolimus oral tablet soluble*
- FOTIVDA
- FRUZAQLA
- GAVRETO
- *gefitinib*
- GILOTRIF
- GLEEVEC
- GLEOSTINE ORAL CAPSULE 10 MG, 100 MG, 40 MG
- GOMEKLI
- IBRANCE
- ICLUSIG
- IDHIFA
- *imatinib mesylate oral*
- IMBRUVICA ORAL CAPSULE
- IMBRUVICA ORAL SUSPENSION
- IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG
- *imkeldi*
- INLYTA
- INQOVI
- INREBIC
- IRESSA
- ITOVEBI
- IWILFIN
- JAKAFI
- JAYPIRCA
- KISQALI (200 MG DOSE)
- KISQALI (400 MG DOSE)
- KISQALI (600 MG DOSE)
- KOSELUGO
- KRAZATI
- *lapatinib ditosylate*
- LAZCLUZE
- *lenalidomide*
- LENVIMA (10 MG DAILY DOSE)
- LENVIMA (12 MG DAILY DOSE)
- LENVIMA (14 MG DAILY DOSE)
- LENVIMA (18 MG DAILY DOSE)
- LENVIMA (20 MG DAILY DOSE)
- LENVIMA (24 MG DAILY DOSE)
- LENVIMA (4 MG DAILY DOSE)
- LENVIMA (8 MG DAILY DOSE)
- LONSURF
- LORBRENA
- LUMAKRAS
- LYNPARZA ORAL TABLET
- LYTGobi (12 MG DAILY DOSE)
- LYTGobi (16 MG DAILY DOSE)
- LYTGobi (20 MG DAILY DOSE)
- MEKINIST
- MEKTOVI
- NERLYNX
- NEXAVAR

- *nilotinib hcl*
- NINLARO
- NUBEQA
- ODOMZO
- OGSIVEO
- OJEMDA ORAL SUSPENSION RECONSTITUTED
- OJEMDA ORAL TABLET 100 MG
- OJJAARA
- ONUREG
- ORGOVYX
- ORSERDU
- *pazopanib hcl*
- PEMAZYRE
- PIQRAY (200 MG DAILY DOSE)
- PIQRAY (250 MG DAILY DOSE)
- PIQRAY (300 MG DAILY DOSE)
- POMALYST
- QINLOCK
- RETEVMO ORAL TABLET
- REVLIMID
- REVUFORJ
- REZLIDHIA
- ROMVIMZA
- ROZLYTREK
- RUBRACA
- RYDAPT
- SCEMBLIX
- *sorafenib tosylate*
- SPRYCEL
- STIVARGA
- *sunitinib malate*
- SUTENT
- TABRECTA
- TAFINLAR
- TAGRISSO
- TALZENNA
- TARGRETIN
- TASIGNA
- TAZVERIK
- TEPMETKO
- THALOMID ORAL CAPSULE 100 MG, 50 MG
- TIBSOVO
- TORPENZ
- TRUQAP ORAL TABLET 200 MG
- TUKYSA
- TURALIO ORAL CAPSULE 125 MG
- TYKERB
- VANFLYTA
- VENCLEXTA
- VENCLEXTA STARTING PACK
- VERZENIO
- VITRAKVI
- VIZIMPRO
- VONJO
- VORANIGO
- VOTRIENT
- WELIREG
- XALKORI
- XOSPATA
- XPOVIO (100 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 50 MG
- XPOVIO (40 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 10 MG
- XPOVIO (40 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 40 MG
- XPOVIO (60 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 60 MG
- XPOVIO (60 MG TWICE WEEKLY)
- XPOVIO (80 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG
- XPOVIO (80 MG TWICE WEEKLY)
- XTANDI
- YONSA
- ZEJULA ORAL TABLET
- ZELBORAF
- ZOLINZA
- ZYDELIG
- ZYKADIA ORAL TABLET
- ZYTIGA

PA Criteria	Criteria Details
Exclusion Criteria	

PA Criteria	Criteria Details
Required Medical Information	Approved when ANY of the following inclusion criteria is met: (1) Drug is FDA approved for indication and regimen requested, (2) The indication and regimen is classified as Category 1 or 2A by National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium, (3) narrative text in The American Hospital Formulary Service-Drug Information (AHFS-DI) or Clinical Pharmacology Compendium is supportive for the specific condition(s) requested, (4) The Micromedex Compendium and the strength of recommendation is listed as Class I, Class IIa, or Class IIb for the specific condition(s) requested, (5) Indication is listed in Lexi-Drugs as ?off label? with evidence level A, (6) supported by Peer-Reviewed Medical Literature as defined in Chapter 15 Section 50.4.5 of the Medicare Benefit Policy Manual
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	(All Indications): Approve if for continuation of therapy.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

ORAL PAH AGENTS 2026

Products Affected

- OPSUMIT
- ORENITRAM
- ORENITRAM MONTH 1
- ORENITRAM MONTH 2
- ORENITRAM MONTH 3

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Pulmonary Arterial Hypertension (PAH) (Initial): (1) Documentation of a diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV. (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography. (3) Documentation of all the following: (a) Mean pulmonary arterial pressure is greater than 20 mm Hg. (b) Pulmonary vascular resistance (PVR) is greater than 2.0 Woods Units (WU). (c) The pulmonary capillary wedge pressure or left ventricular end-diastolic pressure is 15 mm Hg or less.
Age Restrictions	
Prescriber Restrictions	(PAH): Prescribed by or in consultation with a Cardiologist or Pulmonologist
Coverage Duration	(Initial): 6 months. (Continuation):12 months.
Other Criteria	(PAH)(Continuation): Stabilization or improvement as evaluated by a cardiologist or pulmonologist.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

ORENCIA SQ 2026

Products Affected

- ORENCIA CLICKJECT
- ORENCIA SUBCUTANEOUS SOLUTION
PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	(RA, PsA, PJIA): Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
Required Medical Information	Rheumatoid arthritis (RA)(Initial): (1) Diagnosis of RA. (2) Inadequate response or inability to tolerate one DMARD: (e.g. methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine). Psoriatic arthritis (PsA)(Initial): (1) Diagnosis of PsA. Polyarticular Juvenile idiopathic arthritis (PJIA)(Initial): (1) Diagnosis of PJIA. (2) Inadequate response or inability to tolerate one of the following: methotrexate, leflunomide, sulfasalazine.
Age Restrictions	
Prescriber Restrictions	(RA, PJIA): Prescribed by or in consultation with a rheumatologist. (PsA): Prescribed by or in consultation with a dermatologist or rheumatologist.
Coverage Duration	12 months
Other Criteria	(RA, PsA, PJIA)(Reauth): (1) Member demonstrates positive clinical response to therapy
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ORIAHNN 2026

Products Affected

- ORIAHNN

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ORILISSA 2026

Products Affected

- ORILISSA

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ORKAMBI 2026

Products Affected

- ORKAMBI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Cystic Fibrosis (CF)(Initial): (1) Diagnosis of CF, (2) One of the following: (a) Documentation that member is homozygous for the F508del mutation in the CFTR gene (b) If the member's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene
Age Restrictions	(CF): Member is 1 year of age or older for granules. Member is 6 years of age or older for tablets.
Prescriber Restrictions	(CF): Prescribed by or in consultation with pulmonologist or Specialist affiliated with a CF care center
Coverage Duration	12 months
Other Criteria	(CF)(Reauth): Member has had a positive clinical response to therapy
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

ORLADEYO 2026

Products Affected

- ORLADEYO

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

OTEZLA 2026

Products Affected

- OTEZLA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Oral Ulcers Associated with Behcet's Disease (OU-BD)(Initial): (1) Diagnosis of OU-BD. Psoriatic arthritis (PsA)(Initial): (1) Diagnosis of PsA. Plaque psoriasis (PsO)(Initial): (1) Diagnosis of PsO.
Age Restrictions	
Prescriber Restrictions	(PsA, OU-BD): Prescribed by or in consultation with a Rheumatologist or Dermatologist. (PsO): Prescribed by or in consultation with dermatologist.
Coverage Duration	12 months
Other Criteria	(OU-BD, PsA, PsO)(Reauth): (1) Member demonstrates positive clinical response to therapy
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

OVERACTIVE BLADDER AGENTS (OAB) ACH 2026

Products Affected

- OXYTROL
- VESICARE

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

OXERVATE 2026

Products Affected

- OXERVATE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Neurotrophic keratitis (NK)(Initial): (1) Diagnosis of NK. (2) Submission of chart documentation indicating treatment of left eye, right eye, or both (3) Member will not exceed 8 weeks of Oxervate therapy per affected eye(s).
Age Restrictions	
Prescriber Restrictions	Prescribed by or in consultation with an ophthalmologist or Optometrist.
Coverage Duration	8 weeks
Other Criteria	(NK)(Reauth): (1) Submission of chart documentation indicating treatment of left eye, right eye, or both with positive clinical response to therapy (2) Member has received less than or equal to 8 weeks of therapy (one course of therapy) per affected eye(s), (3) Documentation of clinical rationale for treatment greater than 8 weeks (e.g. member has a recurrence of neurotrophic keratitis, or treatment of a different eye), (4) Member will not exceed a total of 16 weeks of Oxervate therapy per affected eye(s).
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

PALYNZIQ 2026

Products Affected

- PALYNZIQ

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

PART D VS EXCLUDED 2026

Products Affected

- CRINONE
- IMVEXXY MAINTENANCE PACK
- IMVEXXY STARTER PACK
- INTRAROSA
- OSPHENA
- VFEND IV
- *voriconazole intravenous*
- ZTLIDO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Subject to additional clinical review for ESRD-related use - if applicable.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

PDE INHIBITOR AGENTS FOR PAH 2026

Products Affected

- ADCIRCA
- ALYQ
- *tadalafil (pah)*

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

PHEBURANE 2026

Products Affected

- PHEBURANE

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

PRALUENT 2026

Products Affected

- PRALUENT SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Hyperlipidemia (HLA) (Initial): (1) Diagnosis of hyperlipidemia, (2) ONE of the following: (A) LDL-C 70 mg/dL or greater after a minimum 8-week trial of at least moderate-intensity statin therapy OR (B) Inability to tolerate statin therapy as documented by one of the following: (i) member had rhabdomyolysis or symptoms with creatine kinase (CK) exceeding 10 times the upper limit of normal (ULN) or (ii) either of the following with TWO statins: myalgia (no CK elevation) or myositis (CK less than 10 times ULN or (iii) hepatotoxicity from statin use (increased AST/ALT exceeding 3 times ULN) or (iv) liver disease documented by Child Pugh A or worse OR AST/ALT exceeding 3 times ULN for at least 6 weeks Atherosclerotic cardiovascular disease (ASCVD) (Initial): (1) Diagnosis of atherosclerotic cardiovascular disease (ASCVD) as diagnosed by either stress test, angiography, atherosclerotic event (e.g. MI, angina, stroke, claudication, carotid stenosis) or arterial intervention for atherosclerotic disease (e.g. coronary, peripheral, carotid), (2) ONE of the following: (A) LDL-C 70 mg/dL or greater after a minimum 8-week trial of at least moderate-intensity statin therapy OR (B) Inability to tolerate statin therapy as documented by one of the following: (i) member had rhabdomyolysis or symptoms with creatine kinase (CK) exceeding 10 times the upper limit of normal (ULN) or (ii) either of the following with TWO statins: myalgia (no CK elevation) or myositis (CK less than 10 times ULN or (iii) hepatotoxicity from statin use (increased AST/ALT exceeding 3 times ULN) or (iv) liver disease documented by Child Pugh A or worse OR AST/ALT exceeding 3 times ULN for at least 6 weeks
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	(Initial): 6 months (Continuation): 2 years

PA Criteria	Criteria Details
Other Criteria	Homozygous Familial Hypercholesterolemia (HoFH) (Initial): (1) Diagnosis of HoFH. (2) One of the following: (a) Untreated LDL-C greater than 500 mg/dL or (b) Treated LDL-C greater than 300 mg/dL. (3) Member is receiving other lipid-lowering therapy (e.g. statin, ezetimibe). (4) Not used in combination with Juxtapid (lomitapide). (HLA, ASVCD)(CONTINUATION): (1) Positive Clinical response to therapy (e.g. reduction in LDL-C levels). (HoFH)(Continuation): (1) Positive Clinical response to therapy (e.g. reduction in LDL-C levels). (2) Member continues to receive other lipid-lowering therapy (e.g. statin, ezetimibe). (3) Not used in combination with Juxtapid (lomitapide).
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

PREFERRED DENOSUMAB 2026

Products Affected

- JUBBONTI

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

PREFERRED GLP-1 AGONISTS 2026

Products Affected

- *liraglutide*
- MOUNJARO SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- OZEMPIC (0.25 OR 0.5 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 2 MG/3ML
- OZEMPIC (1 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 4 MG/3ML
- OZEMPIC (2 MG/DOSE)
- RYBELSUS
- TRULICITY SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	(DM2)(Initial): (1) One of the following: (a) For members requiring ongoing treatment for type 2 diabetes mellitus, submission of medical records (e.g. chart notes) confirming diagnosis of type 2 diabetes mellitus (b) Submission of medical records (e.g. chart notes) confirming diagnosis of type 2 diabetes mellitus as evidenced by one of the following laboratory values (i) A1C greater than or equal to 6.5 percent (ii) Fasting plasma glucose (FPG) greater than or equal to 126 mg/dL (iii) 2-hour plasma glucose (PG) greater than or equal to 200 mg/dL during OGTT (oral glucose tolerance test)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	(DM2)(Reauth): Documentation of positive clinical response to therapy
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

PREFERRED HEPATITIS C AGENTS 2026

Products Affected

- EPCLUSA
- HARVONI
- *ledipasvir-sofosbuvir*
- MAVYRET
- *sofosbuvir-velpatasvir*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	(1) Documentation of member's Hepatitis C Genotype. (2) Prescribed regimen is consistent with the current AASLD/IDSA guidance.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Duration will be applied consistent with AASLD/ IDSA guidance
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

PREFERRED TOCILIZUMAB SQ 2026

Products Affected

- TYENNE SUBCUTANEOUS

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

PREFERRED USTEKINUMAB SQ 2026

Products Affected

- YESINTEK SUBCUTANEOUS

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

PRETOMANID 2026

Products Affected

- *pretomanid*

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

PROCYSBI 2026

Products Affected

- PROCYSBI ORAL PACKET

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

PROMACTA 2026

Products Affected

- *eltrombopag olamine*
- PROMACTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Chronic Idiopathic Thrombocytopenic Purpura (ITP)(Initial): (1) Diagnosis of relapsed/refractory, persistent, or chronic ITP. (2) Baseline platelet count is less than 30,000/mcL. (3) Member's degree of thrombocytopenia and clinical condition increase the risk of bleeding. (4) Inadequate response or inability to tolerate ONE of the following: (a) corticosteroids, (b) immune globulin, (c) splenectomy. First-Line for Severe Aplastic Anemia(FLSAA): (1) Diagnosis of severe aplastic anemia. (2) Used for first-line treatment (i.e., member has not received prior immunosuppressive therapy). (3) Member meets at least TWO of the following: (a) absolute neutrophil count less than 500/mcL, (b) platelet count less than 20,000/mcL, (c) absolute reticulocyte count less than 60,000/mcL. (4) Used in combination with standard immunosuppressive therapy (e.g. Agam [antithymocyte globulin equine] and cyclosporine). Refractory Severe Aplastic Anemia (RSAA)(Initial): (1) Diagnosis of refractory severe aplastic anemia. (2) Member has a platelet count less than 30,000/mcL. (3) Inadequate response or inability to tolerate immunosuppressive therapy with antithymocyte globulin and cyclosporine. Chronic Hepatitis C-Associated Thrombocytopenia (HEPC-TP)(Initial): (1) Diagnosis of chronic hepatitis C-associated thrombocytopenia. (2) One of the following: (a) Planning to initiate and maintain interferon-based treatment, or (b) currently receiving interferon-based treatment.
Age Restrictions	
Prescriber Restrictions	(ITP, FLSAA, RSAA): Prescribed by or in consultation with hematologist/oncologist. (HEPC-TP): Prescribed by or in consultation with Hematologist/oncologist, Gastroenterologist, Hepatologist, Infectious disease specialist, HIV specialist.
Coverage Duration	(ITP).=12mo.(FLSAA)=6mo.(RSAA)Initial=6mo.(HEPC-TP)Initial=3mo.(RSAA,HEPC-TP)Cont.=12mo.

PA Criteria	Criteria Details
Other Criteria	(ITP, RSAA)(Continuation): (1) Positive clinical response to therapy as evidenced by an increase in platelet count to a level sufficient to avoid clinically important bleeding. (HEPC-TP)(Continuation): (1) ONE of the following: (A) For members that started treatment with Promacta prior to initiation of treatment with interferon, both of the following: (i) Member is currently on antiviral interferon therapy for treatment of chronic hepatitis C, AND (ii) member reached a threshold platelet count that allows initiation of antiviral interferon therapy with Promacta treatment by week 9. (B) For members that started treatment with Promacta while on concomitant treatment with interferon, member is currently on antiviral interferon therapy for treatment of chronic hepatitis C.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

PYRUKYND 2026

Products Affected

- PYRUKYND
- PYRUKYND TAPER PACK

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

QBREXZA 2026

Products Affected

- QBREXZA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Primary Axillary Hyperhidrosis (PAH) (Initial) (1) Diagnosis of primary axillary hyperhidrosis: (2) Hyperhidrosis Disease Severity Scale grade 3 or 4 (3) Other causes of axillary hyperhidrosis have been ruled out (e.g., menopause, medications) (4) Disease frequently interferes with daily activities (e.g., daily clothes changes required)
Age Restrictions	
Prescriber Restrictions	Prescribed by or in consultation with a dermatologist, primary care physician, internist, or pediatrician.
Coverage Duration	(Initial, Reauth): 12 months
Other Criteria	(PAH)(Reauth): (1) Member demonstrates positive clinical response to therapy
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

QUALAQUIN 2026

Products Affected

- *quinine sulfate oral*

PA Criteria	Criteria Details
Exclusion Criteria	Use for treatment or prevention of nocturnal leg cramps
Required Medical Information	Uncomplicated Malaria: (1) Diagnosis of uncomplicated malaria due to (a) plasmodium falciparum malaria or (b) plasmodium vivax . (2) One of the following: (a) Both of the following: (i) treatment in areas of chloroquine-sensitive malaria (ii) Inadequate response or inability to tolerate chloroquine or hydroxychloroquine, or (b) treatment in areas of chloroquine-resistant malaria. Babesiosis: (1) Diagnosis of babesiosis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Babesiosis: 10 days Uncomplicated Malaria: 14 Days
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

QULIPTA 2026

Products Affected

- QULIPTA

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

QUVIVIQ 2026

Products Affected

- QUVIVIQ

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

RADICAVA 2026

Products Affected

- RADICAVA ORS STARTER KIT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Amyotrophic Lateral Sclerosis (ALS)(Initial): (1) Diagnosis of definite or probable ALS per the revised El Escorial World Federation of Neurology criteria. (2) Normal respiratory function defined as forced vital capacity (FVC) of greater than or equal to 80% at the start of treatment. (3) Scores of 2 points or greater on each individual item of the ALS Functional Rating Scale-revised (ALSFRS-R).
Age Restrictions	
Prescriber Restrictions	(ALS): Prescribed by or in consultation with a neurologist with expertise in the diagnosis of ALS
Coverage Duration	6 months.
Other Criteria	(ALS)(Reauth): (1) Member shows benefit from therapy (e.g. slowing of decline of functional abilities).
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

RALDESY 2026

Products Affected

- RALDESY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Major depressive disorder (MDD): (1) Diagnosis of major depressive disorder (MDD) (2) One of the following: (a) inadequate response or inability to tolerate both of the following: (i) generic formulary trazadone tablets (ii) generic formulary serotonin reuptake inhibitors (SSRI) OR (b) Member is unable to swallow tablets.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	(All Indications): Approve if for continuation of therapy.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

RAVICTI 2026

Products Affected

- RAVICTI

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

RECORLEV 2026

Products Affected

- RECORLEV

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

REPATHA 2026

Products Affected

- REPATHA
- REPATHA PUSHTRONEX SYSTEM
- REPATHA SURECLICK

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

RESPIRATORY ENZYMES 2026

Products Affected

- ARALAST NP INTRAVENOUS SOLUTION RECONSTITUTED 1000 MG
- GLASSIA INTRAVENOUS SOLUTION 1000 MG/50ML
- PROLASTIN-C INTRAVENOUS SOLUTION
- ZEMAIRA INTRAVENOUS SOLUTION RECONSTITUTED 1000 MG

PA Criteria	Criteria Details
Exclusion Criteria	(ATT): (1) IgA deficiency with known anti-IgA antibody. (2) Member is a smoker
Required Medical Information	Part D is medically necessary when there is documentation of: Alpha 1-antitrypsin (AAT) deficiency: (1) Submission of medical records showing diagnosis of congenital alpha1-antitrypsin deficiency as confirmed by ONE of the following: (a) PiZZ, PiZ(null) or Pi(null)(null) protein phenotypes (homozygous) OR (B) Other rare AAT disease-causing alleles associated with serum alpha1-antitrypsin (AAT) level less than 11uM/L (2) Submission of medical records showing clinical evidence of chronic emphysema without evidence of alpha 1-antitrypsin-associated liver disease (3) Member has a low serum concentration of alpha 1-antitrypsin (AAT) less than 80 mg/dL (radial immunodiffusion) or 50 mg/dl (nephelometry) or less than 11 uM/L (nephelometry) or less than 0.8 g/L (35 percent of normal)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

REXULTI 2026

Products Affected

- REXULTI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Alzheimer's disease (AD): (1) Diagnosis of agitation associated with dementia due to Alzheimer's disease in adults. Schizophrenia: (1) Diagnosis of schizophrenia (2) Inadequate response or inability to tolerate TWO of the following: aripiprazole, quetiapine, asenapine, olanzapine, paliperidone, risperidone, ziprasidone. Major Depressive Disorder (MDD): (1) Diagnosis of major depressive disorder and as adjunctive therapy to antidepressants (2) Inadequate response or inability to tolerate aripiprazole and quetiapine
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	(All Indications): Approve if for continuation of therapy.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

REZDIFFRA 2026

Products Affected

- REZDIFFRA

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

REZUROCK 2026

Products Affected

- REZUROCK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Chronic graft-versus-host disease (cGVHD) (Initial): (1) Diagnosis of chronic graft-versus-host disease, (2) Inadequate response or inability to tolerate two or more lines of systemic therapy (e.g. corticosteroids, mycophenolate, etc.)
Age Restrictions	
Prescriber Restrictions	(cGVHD): Prescribed by or in consultation with one of the following (1) Hematologist, (2) Oncologist, (3) physician experienced in the management of transplant patients
Coverage Duration	12 months
Other Criteria	(cGVHD) (Reauth): (1) Member does not show evidence of progressive disease while on therapy
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

RINVOQ 2026

Products Affected

- RINVOQ

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

RINVOQ LQ 2026

Products Affected

- RINVOQ LQ

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with any other biologic disease modifying antirheumatic drug (DMARD), other JAK inhibitors, or potent immunosuppressants (e.g. azathioprine, cyclosporine).
Required Medical Information	Psoriatic Arthritis (PsA)(Initial): (1) Diagnosis of PsA, (2) Member had an inadequate response or inability to tolerate one or more TNF inhibitors (e.g. Enbrel, Adalimumab-AACF) or documentation demonstrating that a trial may be inappropriate. Polyarticular Juvenile Idiopathic Arthritis (PJIA)(Initial): (1) Diagnosis of active PJIA, (2) Inadequate response or inability to tolerate ONE of the following: Methotrexate, Leflunomide, Sulfasalazine (3) Member had an inadequate response or inability to tolerate one or more TNF inhibitors (e.g. Enbrel, Adalimumab-AACF) or documentation demonstrating that a trial may be inappropriate.
Age Restrictions	
Prescriber Restrictions	(PsA): Prescribed by or in consultation with a rheumatologist or dermatologist. (pJIA): Prescribed by or in consultation with a rheumatologist
Coverage Duration	12 months
Other Criteria	(PsA, pJIA)(Reauth): (1) Member demonstrates positive clinical response to therapy
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

RIVFLOZA 2026

Products Affected

- RIVFLOZA

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

SEROSTIM 2026

Products Affected

- SEROSTIM SUBCUTANEOUS SOLUTION
RECONSTITUTED 4 MG, 5 MG, 6 MG

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

SIGNIFOR 2026

Products Affected

- SIGNIFOR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Cushing's disease (CD)(Initial): (1) Diagnosis of (pituitary) Cushing's disease. (2) Pituitary surgery is not an option or has not been curative
Age Restrictions	
Prescriber Restrictions	(CD) Prescribed by or in consultation with an endocrinologist.
Coverage Duration	12 months
Other Criteria	(CD)(Reauth): Documentation of positive clinical response (e.g. clinically meaningful reduction in 24- hour urinary free cortisol levels, improvement in signs or symptoms of the disease)
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

SILDENAFIL 2026

Products Affected

- REVATIO ORAL TABLET
- *sildenafil citrate oral suspension reconstituted*
- *sildenafil citrate oral tablet 20 mg*

PA Criteria	Criteria Details
Exclusion Criteria	(PAH, RP): Documentation of concomitant nitrate use
Required Medical Information	Pulmonary Arterial Hypertension (PAH): (1) Diagnosis of PAH WHO Group I with New York Heart Association (NYHA) Functional Class II to IV (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography (3) Documentation of all the following: (a) Mean pulmonary arterial pressure is greater than 20 mm Hg. (b) Pulmonary vascular resistance (PVR) is greater than 2.0 Woods Units (WU). (c) The pulmonary capillary wedge pressure or left ventricular end-diastolic pressure is 15 mm Hg or less. Raynaud's Phenomenon (RP): (1) Diagnosis of secondary Raynaud's phenomenon. (2) Inadequate response or inability to tolerate a calcium channel blocker.
Age Restrictions	
Prescriber Restrictions	(PAH): Prescribed by or in consultation with a Cardiologist or Pulmonologist
Coverage Duration	Indefinite
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

SILIQ 2026

Products Affected

- SILIQ

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

SIMPONI 2026

Products Affected

- SIMPONI SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- SIMPONI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
Required Medical Information	Ankylosing Spondylitis (AS)(Initial): (1) Diagnosis of AS. (2) Inadequate response or inability to tolerate two of the following: (a) Adalimumab (i.e. Adalimumab-AACF), (b) etanercept (Enbrel), (c) secukinumab (Cosentyx), (d) tofacitinib (Xeljanz/Xeljanz XR), (e) upadacitinib (Rinvoq) or documentation demonstrating that a trial may be inappropriate. Psoriatic Arthritis (PsA)(Initial): (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Adalimumab-AACF), (b) Enbrel, (c) Xeljanz/Xeljanz XR, (d) Rinvoq/Rinvoq LQ, (e) Skyrizi, (f) Cosentyx, (g) Ustekinumab (i.e. Yesintek), (h) Orencia, (i) Otezla OR documentation demonstrating that a trial may be inappropriate. Rheumatoid arthritis (RA)(Initial): (1) Diagnosis of moderate to severe RA. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Adalimumab-AACF), (b) Enbrel, (c) Rinvoq, (d) Xeljanz/Xeljanz XR, (e) Orencia OR documentation demonstrating that a trial may be inappropriate. Ulcerative Colitis (UC)(Initial): (1) Diagnosis of moderate to severe UC. (2) Inadequate response or inability to tolerate two of the following: (a) Adalimumab (i.e. Adalimumab-AACF), and (b) Xeljanz/Xeljanz XR, (c) Ustekinumab (i.e. Yesintek), (d) Rinvoq, (e) Skyrizi OR documentation demonstrating that a trial may be inappropriate.
Age Restrictions	
Prescriber Restrictions	(RA, AS): Prescribed by or in consultation with a rheumatologist. (PsA): Prescribed by or in consultation with a rheumatologist or dermatologist. (UC): Prescribed by or in consultation with a gastroenterologist.
Coverage Duration	12 months
Other Criteria	(AS, PsA, RA, UC)(Reauth): (1) Member demonstrates positive clinical response to therapy
Indications	All Medically-accepted Indications.

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

SIRTURO 2026

Products Affected

- SIRTURO

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

SKYCLARYS 2026

Products Affected

- SKYCLARYS

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

SKYRIZI SC 2026

Products Affected

- SKYRIZI PEN
- SKYRIZI SUBCUTANEOUS

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

SKYTROFA 2026

Products Affected

- SKYTROFA

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

SOGROYA 2026

Products Affected

- SOGROYA

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

SOHONOS 2026

Products Affected

- SOHONOS

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

SOTATERCEPT 2026

Products Affected

- WINREVAIR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Pulmonary Arterial Hypertension (PAH) (Initial): (1) Diagnosis of PAH WHO Group I with New York Heart Association (NYHA) Functional Class II to III (2) inadequate response or inability to tolerate TWO of the following: (a) Endothelin Receptor Antagonist (bosentan, ambrisentan, macitentan) (b) Phosphodiesterase 5 inhibitor (tadalafil, sildenafil) (c) IV prostacyclin therapy (treprostinil, epoprostenol) (3) Member continues to receive other PAH therapies (e.g. ambrisentan, tadalafil)
Age Restrictions	
Prescriber Restrictions	(PAH): Prescribed by or in consultation with cardiologist or pulmonologist.
Coverage Duration	(Initial) 6 months (Reauth) 12 months
Other Criteria	(PAH)(Reauth): Stabilization or improvement as evaluated by a cardiologist or pulmonologist.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

SOTYKTU 2026

Products Affected

- SOTYKTU

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

SPEVIGO SQ 2026

Products Affected

- SPEVIGO SUBCUTANEOUS SOLUTION
PREFILLED SYRINGE 150 MG/ML

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

SUNOSI 2026

Products Affected

- SUNOSI

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

SYMDEKO 2026

Products Affected

- SYMDEKO

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

TADALAFIL (BPH) 2026

Products Affected

- *tadalafil oral tablet 2.5 mg, 5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	(BPH): Concurrent use of nitrates.
Required Medical Information	Benign prostatic hyperplasia (BPH): (1) Diagnosis of BPH. (2) Inadequate response or inability to tolerate an alpha blocker (e.g. tamsulosin, terazosin) or a 5-alpha reductase inhibitor (e.g. dutasteride, finasteride).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TADLIQ 2026

Products Affected

- TADLIQ

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TAFAMIDIS 2026

Products Affected

- VYNDAMAX
- VYNDAQEL

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

TAKHZYRO 2026

Products Affected

- TAKHZYRO

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

TALTZ 2026

Products Affected

- TALTZ

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
Required Medical Information	Plaque Psoriasis (PsO)(Initial): (1) Diagnosis of moderate to severe PsO. (2) ONE of the following: (A) For members 6 to 17 years of age: an inadequate response or inability to tolerate two of the following: (a) Enbrel, (b) Cosentyx, (c) Ustekinumab (i.e. Yesintek) or documentation demonstrating that a trial may be inappropriate, OR (B) For members 18 years of age or older: an inadequate response or inability to tolerate two of the following: (a) Cosentyx (b) Enbrel (c) Adalimumab (i.e. Adalimumab-AACF) (d) Skyrizi, (e) Ustekinumab (i.e. Yesintek), (f) Otezla or documentation demonstrating that a trial may be inappropriate. Psoriatic arthritis (PsA)(Initial): (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate TWO of the following: (a) Enbrel (b) Adalimumab(i.e. Adalimumab-AACF) (c) Cosentyx (d) Rinvoq/Rinvoq LQ (e) Skyrizi (f) Ustekinumab (i.e. Yesintek) (g) Xeljanz/Xeljanz XR, (h) Orencia, (i) Otezla OR documentation demonstrating that a trial may be inappropriate. Ankylosing spondylitis (AS)(Initial): (1) Diagnosis of AS. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Adalimumab-AACF), (b) etanercept (Enbrel), (c) secukinumab (Cosentyx), (d) upadacitinib (Rinvoq), (e) tofacitinib (Xeljanz/Xeljanz XR) OR documentation demonstrating that a trial may be inappropriate. Non-Radiographic Axial Spondyloarthritis (nr-axSpA)(Initial): (1) Diagnosis of nr-axSpA. (2) Inadequate response or inability to tolerate Rinvoq OR Cosentyx OR documentation demonstrating that a trial may be inappropriate (3) Inadequate response or inability to tolerate one NSAID (e.g. ibuprofen, meloxicam, naproxen).
Age Restrictions	
Prescriber Restrictions	(PsO): Prescribed by or in consultation with a dermatologist. (PsA): Prescribed by or in consultation with a dermatologist or rheumatologist. (AS, nr-axSpA): Prescribed by or in consultation with a rheumatologist.
Coverage Duration	12 months

PA Criteria	Criteria Details
Other Criteria	(PsA, AS, nr-axSpA, PsO)(Reauth): (1) Member demonstrates positive clinical response to therapy
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TARPEYO 2026

Products Affected

- TARPEYO

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TASIMELTEON 2026

Products Affected

- *tasimelteon*

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

TAVALISSE 2026

Products Affected

- TAVALISSE

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TAVNEOS 2026

Products Affected

- TAVNEOS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Severe Active Anti-neutrophil Cytoplasmic Autoantibody (ANCA)-associated Vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) (ANCA-V(GPA)(MPA))(Initial): (1) Diagnosis of Severe Active Anti-neutrophil Cytoplasmic Autoantibody (ANCA)-associated Vasculitis (granulomatosis with polyangiitis [GPA] or microscopic polyangiitis [MPA]), (2) Used as adjunct to standard therapy, and glucocorticoids (3) Member is on concurrent immunosuppressant therapy with cyclophosphamide or rituximab (Rituxan).
Age Restrictions	
Prescriber Restrictions	(ANCA-V(GPA)(MPA))Prescribed by or in consultation with a nephrologist, pulmonologist, or rheumatologist.
Coverage Duration	(Initial): 6 Months (Reauth): 1 year
Other Criteria	(ANCA-V(GPA)(MPA))(Reauth): (1) Positive clinical response to therapy defined as sustained remission as assessed by the Birmingham Vasculitis Activity Score (BVAS). (2) Reduction in use of glucocorticoids for treatment (3) Member is on concurrent immunosuppressant therapy with cyclophosphamide or rituximab (Rituxan).
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

TERIPARATIDE 2026

Products Affected

- BONSITY 560 mcg/2.24ml
- FORTEO SUBCUTANEOUS SOLUTION PEN-INJECTOR 560 MCG/2.24ML
- *teriparatide subcutaneous solution pen-injector*

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TESTOSTERONE PRODUCTS 2026

Products Affected

- AVEED 12.5 mg/act (1%), 20.25 mg/1.25gm (1.62%),
- DEPO-TESTOSTERONE INTRAMUSCULAR SOLUTION 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 40.5 mg/2.5gm (1.62%), 50 mg/5gm (1%)
- JATENZO • testosterone transdermal solution
- testosterone cypionate intramuscular solution 100 mg/ml, 200 mg/ml • TLANDO
- testosterone enanthate intramuscular solution • UNDECATREX
- testosterone transdermal gel 10 mg/act (2%), • XYOSTED

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Delayed Puberty (DP): (1) Diagnosis of delayed puberty in male members (Applies to Testosterone Enanthate only). Breast Cancer (BC): (1) Diagnosis of inoperable breast cancer in female members (Applies to Testosterone Enanthate only) (2) Used for palliative treatment Hypogonadism (HG)(New starts only): (1) Attestation that diagnosis was initially confirmed by ALL of the following: (A) Two early morning total testosterone levels below 300 ng/dL measured on separate occasions, (B) Normal Prolactin Level, and (C) Physical or cognitive symptoms of testosterone deficiency (e.g. physical: fatigue, sleep disturbances, decreased activity, cognitive: depressive symptoms, cognitive dysfunction, loss of concentration, poor memory, irritability), (2) ONE of the following (A) negative history of prostate and breast cancer OR (B) Both of the following (i) history of prostate cancer with stable PSA less than or equal to 4ng/dL for 2 years and (ii) documentation that the risk versus benefit has been assessed.
Age Restrictions	(HG) Member is 12 years of age or older (applies to generic testosterone cypionate only) and member is 18 years of age or older for all other products
Prescriber Restrictions	
Coverage Duration	(DP, BC): Indefinite (HG)(New Starts, Continuation): Indefinite
Other Criteria	(HG)(Continuation): ONE of the following (1) negative history of prostate and breast cancer OR (2) Both of the following (a) history of prostate cancer with stable PSA less than or equal to 4ng/dL for 2 years and (b) documentation that the risk versus benefit has been assessed
Indications	All Medically-accepted Indications.

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

TETRABENAZINE 2026

Products Affected

- tetrabenazine

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Tardive Dyskinesia (TD)(Initial): (1) Diagnosis of TD, (2) Documentation is provided of ONE of the following: (a) Persistent symptoms of tardive dyskinesia despite a trial of dose reduction, tapering or discontinuation of the offending medication, or (b) Member is not a candidate for a trial of dose reduction, tapering, or discontinuation of the offending medication. Tourette's Syndrome (TS): (1) Diagnosis of TS, (2) Member has tics associated with Tourette's syndrome, (3) Inadequate response or inability to tolerate haloperidol or risperidone. Chorea- Huntington's Disease (CHD): (1) Diagnosis of chorea associated with Huntington's disease
Age Restrictions	
Prescriber Restrictions	(TS, CHD): Prescribed by or in consultation with a neurologist or a psychiatrist. (TD): Prescribed by or in consultation with a neurologist or a psychiatrist.
Coverage Duration	(TD)(Initial): 3 months. (TD)(Reauth): Indefinite. (TS, CHD): Indefinite.
Other Criteria	(TD)(Reauth): Positive clinical response to therapy.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TOLVAPTAN 2026

Products Affected

- *tolvaptan*

PA Criteria	Criteria Details
Exclusion Criteria	(1) Members who are unable to sense or appropriately respond to thirst, (2) hypovolemic hyponatremia, (3) concomitant use of strong CYP3A inhibitors (4) Anuria (5) Autosomal dominant polycystic kidney disease (ADPKD)
Required Medical Information	Hyponatremia (HN) (1) Diagnosis of clinically significant hypervolemic or euvolemic hyponatremia. (2) One of the following: (a) serum sodium less than 125meq/L or (b) serum sodium 125-134meq/L with symptoms (e.g., nausea, vomiting, headache, lethargy, confusion, etc.) (3) Treatment has been initiated or re-initiated in a hospital setting prior to discharge within the past 30 days. (4) Inadequate response or inability to tolerate therapies to control hyponatremia (e.g., fluid restriction, diuretics, etc.).
Age Restrictions	
Prescriber Restrictions	Hyponatremia: Prescribed by or in consultation with a cardiologist, endocrinologist or nephrologist
Coverage Duration	12 months
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TOPICAL CHEMO AGENTS 2026

Products Affected

- *bexarotene*
- TARGRETIN
- VALCHLOR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Approved when ANY of the following inclusion criteria is met: (1) Drug is FDA approved for indication and regimen requested, (2) The indication and regimen is classified as Category 1 or 2A by National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium, (3) narrative text in The American Hospital Formulary Service-Drug Information (AHFS-DI) or Clinical Pharmacology Compendium is supportive for the specific condition(s) requested, (4) The Micromedex Compendium and the strength of recommendation is listed as Class I, Class IIa, or Class IIb for the specific condition(s) requested, (5) Indication is listed in Lexi-Drugs as ?off label? with evidence level A, (6) supported by Peer-Reviewed Medical Literature as defined in Chapter 15 Section 50.4.5 of the Medicare Benefit Policy Manual
Age Restrictions	
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or dermatologist
Coverage Duration	Indefinite
Other Criteria	(All Indications): Approve if for continuation of therapy.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

TOPICAL RETINOID PRODUCTS 2026

Products Affected

- *adapalene external cream*
- *adapalene external gel 0.3 %*
- *adapalene external pad*
- *adapalene-benzoyl peroxide external gel*
- AKLIEF
- ALTRENO
- ATRALIN
- CABTREO
- *clindamycin-tretinoin*
- DIFFERIN EXTERNAL CREAM
- DIFFERIN EXTERNAL GEL 0.3 %
- EPIDUO
- EPIDUO FORTE
- RETIN-A
- RETIN-A MICRO
- RETIN-A MICRO PUMP EXTERNAL GEL 0.06 %, 0.08 %
- *tretinoin external*
- *tretinoin microsphere external gel 0.04 %, 0.1 %*
- *tretinoin microsphere pump external gel 0.08 %*
- TWYNEO
- ZIANA

PA Criteria	Criteria Details
Exclusion Criteria	Cosmetic use
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

TRACLEER 2026

Products Affected

- TRACLEER

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Pulmonary Arterial Hypertension (PAH) (Initial): (1) Documentation of a diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV. (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography. (3) Documentation of all the following: (a) Mean pulmonary arterial pressure is greater than 20 mm Hg. (b) Pulmonary vascular resistance (PVR) is greater than 2.0 Woods Units (WU). (c) The pulmonary capillary wedge pressure or left ventricular end-diastolic pressure is 15 mm Hg or less. (4) Inadequate response or inability to tolerate generic bosentan.
Age Restrictions	
Prescriber Restrictions	(PAH): Prescribed by or in consultation with a Cardiologist or Pulmonologist
Coverage Duration	(Initial): 6 months. (Continuation):12 months.
Other Criteria	(PAH)(Continuation): Stabilization or improvement as evaluated by a cardiologist or pulmonologist.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TREMFYA SQ 2026

Products Affected

- TREMFYA CROHNS INDUCTION
- TREMFYA ONE-PRESS
- TREMFYA PEN SUBCUTANEOUS SOLUTION
AUTO-INJECTOR 200 MG/2ML
- TREMFYA SUBCUTANEOUS SOLUTION
REFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
Required Medical Information	Plaque psoriasis (PsO)(Initial): (1) Diagnosis or moderate to severe PsO. (2) Inadequate response or inability to tolerate two of the following: (a) Cosentyx, (b) Enbrel, (c) Adalimumab (i.e. Adalimumab-AACF), (d) Skyrizi, (e) Ustekinumab (i.e. Yesintek) , (f) Otezla OR documentation demonstrating that a trial may be inappropriate. Psoriatic arthritis (PsA)(Initial): (1) Diagnosis of PsA, (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Adalimumab-AACF) (b) Enbrel (c) Cosentyx (d) Rinvoq/Rinvoq LQ (e) Skyrizi (f) Ustekinumab (i.e. Yesintek) (g) Xeljanz/Xeljanz XR, (h) Orencia, (i) Otezla or documentation demonstrating that a trial may be inappropriate. Ulcerative colitis (UC) (Initial): (1) Diagnosis of moderately to severely active UC (2) ONE of the following: (a) Inadequate response or inability to tolerate two of the following: (i) Adalimumab (i.e. Adalimumab-AACF), (ii) ustekinumab (Stelara i.e. Yesintek), (iii) upadacitinib (Rinvoq), (iv) tofacitinib (Xeljanz/Xeljanz XR), (v) risankizumab (Skyrizi) OR documentation demonstrating that a trial may be inappropriate (b) Will be used as a maintenance dose following the intravenous induction doses. Crohn's Disease (CD)(Initial): (1) Diagnosis of moderately to severely active CD (2) One of the following: (A) Inadequate response or inability to tolerate two of the following: (a) Adalimumab (i.e. Adalimumab-AACF), (b) Ustekinumab (i.e. Yesintek), (c) Skyrizi, (d) Rinvoq or documentation demonstrating that a trial may be inappropriate. (B) Will be used as a maintenance dose following the intravenous induction doses
Age Restrictions	
Prescriber Restrictions	(PsO): Prescribed by or in consultation with a dermatologist. (PsA): Prescribed by or in consultation with a dermatologist or rheumatologist. (UC,CD): Prescribed by or in consultation with a gastroenterologist
Coverage Duration	12 months

PA Criteria	Criteria Details
Other Criteria	(PsO, PsA, UC, CD)(Reauth): (1) Member demonstrates positive clinical response to therapy
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TRIKAFTA 2026

Products Affected

- TRIKAFTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Cystic Fibrosis (CF)(Initial): (1) Diagnosis of Cystic Fibrosis. (2) One of the following: (a) Documentation that member has at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene as detected by an FDA-cleared cystic fibrosis mutation test (b) A mutation in the CFTR gene that is responsive based on in vitro data. (c) If the member's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene
Age Restrictions	
Prescriber Restrictions	(CF): Prescribed by or in consultation with a pulmonologist or Specialist affiliated with a CF care center
Coverage Duration	12 months
Other Criteria	(CF)(Reauth): Member has had a positive clinical response to therapy
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

TRYNGOLZA 2026

Products Affected

- TRYNGOLZA

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TRYVIO 2026

Products Affected

- TRYVIO

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TYMLOS 2026

Products Affected

- TYMLOS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Postmenopausal Osteoporosis (PMO) (Initial): (1) Diagnosis of PMO. (2) Member has severe osteoporosis or is at a high to very high risk for fracture as defined by ONE of the following: (a) Member has a history of multiple vertebral fractures, (b) T score of the individual's bone mineral density (BMD) is at least -2.5 standard deviations below the young adult mean OR (c) history of osteoporotic fracture (i.e. Low-trauma fracture of the hip, spine, pelvis, or distal forearm, etc.) (3) Inadequate response or inability to tolerate ONE of the following: (a) bisphosphonates, (b) hormone replacement therapy, (c) selective-estrogen receptor modulators (SERMs), OR (d) Denosumab (Prolia). Osteoporosis at high risk for fracture in men (OSTm) (Initial): (1) Diagnosis of primary or hypogonadal osteoporosis (2) Both of the following: (a) Bone mineral density (BMD) T-score of -2.5 or lower in the lumbar spine, femoral neck, total hip, or radius (one-third radius site) (b) One of the following (i) History of low-trauma fracture of the hip, spine, pelvis, or distal forearm (ii) inadequate response or inability to tolerate at least one osteoporosis treatment (e.g. alendronate, risedronate, zoledronic acid, Prolia [denosumab])
Age Restrictions	(PMO, OSTm) Member is 18 years of age or older
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	(PMO, OSTm)(Reauth): Cumulative lifetime therapy does not exceed 2 years
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

TYVASO DPI 2026

Products Affected

- TYVASO DPI MAINTENANCE KIT INHALATION
POWDER 16 MCG, 32 MCG, 48 MCG, 64 MCG
- TYVASO DPI TITRATION KIT INHALATION
POWDER 16 & 32 & 48 MCG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Pulmonary Arterial Hypertension (PAH) (Initial): (1) Diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV. (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography. (3) Documentation of all the following: (a) Mean pulmonary arterial pressure is greater than 20 mm Hg. (b) Pulmonary vascular resistance (PVR) is greater than 2.0 Woods Units (WU). (c) The pulmonary capillary wedge pressure or left ventricular end-diastolic pressure is 15 mm Hg or less. Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) (Initial): (1) Diagnosis of pulmonary hypertension associated with interstitial lung disease (PHILD) WHO Group 3. (2) Diagnosis confirmed by diagnostic test(s) (e.g. right heart catheterization, doppler echocardiogram, computerized tomography imaging).
Age Restrictions	
Prescriber Restrictions	(PAH)(PH-ILD): Prescribed by or in consultation with a Cardiologist or Pulmonologist
Coverage Duration	(Initial): 6 months. (Continuation): 12 months.
Other Criteria	(PAH)(PH-ILD)(CONTINUATION): Stabilization or improvement as evaluated by a cardiologist or pulmonologist.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

UBRELVY 2026

Products Affected

- UBRELVY

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

UPTRAVI 2026

Products Affected

- UPTRAVI ORAL
- UPTRAVI TITRATION

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

VECAMEYL 2026

Products Affected

- VECAMEYL

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

VELSIPITY 2026

Products Affected

- VELSIPITY

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

VEOZAH 2026

Products Affected

- VEOZAH

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	(VMS)(Initial): (1) Diagnosis of moderate to severe vasomotor symptoms due to menopause (2) Inadequate response or inability to tolerate one of the following (a) menopausal hormone therapy (e.g. estradiol tablets) (b) non-hormonal therapy (e.g. paroxetine, venlafaxine, clonidine, etc.) (3) ONE of the following: (a) Aminotransferase is does not exceed 2 x the upper limit of normal (ULN) (b) The total bilirubin does not exceed 2 x the upper limit of normal (ULN) for the evaluating laboratory.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	(VMS)(Initial): 6 months, (Reauth): 12 months
Other Criteria	(VMS)(Reauth): (1) Documentation of positive clinical response to therapy (e.g. decrease in frequency and severity of vasomotor symptoms from baseline, etc.) (2) Member is not experiencing signs or symptoms that may suggest liver injury (new onset fatigue, decreased appetite, nausea, vomiting, pruritus, jaundice, pale feces, dark urine, or abdominal pain) (3) One of the following: (i) Transaminase elevations does not exceed 5 x the upper limit of normal (ULN), OR (ii) Does not exceed 3 x the ULN and the total bilirubin level does not exceed 2 x ULN.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

VERKAZIA 2026

Products Affected

- VERKAZIA

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

VERQUVO 2026

Products Affected

- VERQUVO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Chronic Heart Failure (CHF) (Initial): (1) Diagnosis of chronic heart failure. (2) Member has New York Heart Association (NYHA) Class II, III, or IV symptoms (3) Ejection fraction less than 45 percent (4) One of the following: (a) Member was hospitalized for heart failure within the last 6 months (b) Member used outpatient intravenous diuretics (e.g., bumetanide, furosemide) for heart failure within the last 3 months (5) Inadequate response or inability to tolerate TWO of the following: (a) Angiotensin converting enzyme (ACE) inhibitor (e.g., captopril, enalapril) (b) Angiotensin II receptor blocker (ARB) (e.g., candesartan, valsartan) (c) Angiotensin receptor-neprilysin inhibitor (ARNI) [e.g., Entresto (sacubitril and valsartan)] (d) Beta blocker (e.g. bisoprolol, carvedilol, metoprolol succinate ER) (e) Sodium-glucose co-transporter 2 (SGLT2) inhibitor [e.g., Jardiance (empagliflozin), Farxiga (dapagliflozin), Xigduo XR (dapagliflozin and metformin)] (f) Mineralocorticoid receptor antagonist (MRA) [e.g., eplerenone, spironolactone]
Age Restrictions	
Prescriber Restrictions	(CHF) (Initial): Prescribed by or in consultation with a Cardiologist
Coverage Duration	12 months
Other Criteria	(CHF) (Cont): Documentation of positive clinical response to therapy.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

VIGAFYDE SOLUTION 2026

Products Affected

- VIGAFYDE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Infantile spasm: (1) Diagnosis of infantile spasm (2) Inadequate response or inability to tolerate Vigpoder or Vigabatrín powder for oral solution
Age Restrictions	
Prescriber Restrictions	Prescribed by or in consultation with neurologist/epilepsy specialist
Coverage Duration	Indefinite
Other Criteria	(All Indications): Approve if for continuation of therapy.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

VIJOICE 2026

Products Affected

- VIJOICE

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

VIVJOA 2026

Products Affected

- VIVJOA

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

VOQUEZNA PAK 2026

Products Affected

- VOQUEZNA DUAL PAK
- VOQUEZNA TRIPLE PAK

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

VOQUEZNA TABLETS 2026

Products Affected

- VOQUEZNA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	(H. pylori): (1) Diagnosis of Helicobacter pylori infection (2) One of the following: (a) Used in combination with amoxicillin and clarithromycin for the treatment of H. pylori infection OR (b) Used in combination with amoxicillin for the treatment of H. pylori infection (3) An inadequate response or inability to tolerate ONE of the following: (a) Clarithromycin based therapy (e.g. clarithromycin based triple therapy, clarithromycin based concomitant therapy) OR (b) Bismuth quadruple therapy (e.g. bismuth and metronidazole and tetracycline and proton pump inhibitor [PPI]). Erosive Esophagitis (EE): (1) ONE of the following: (a) Used for healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis OR (b) Used to maintain healing and relief of heartburn associated with erosive esophagitis (2) An inadequate response or inability to tolerate TWO of the following generic proton pump inhibitors (PPI?s): omeprazole, esomeprazole, pantoprazole, lansoprazole, rabeprazole, and dexlansoprazole.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	H. pylori: 1 month Healing of EE: 8 weeks. Maintenance of EE: 6 month GERD: 1 month
Other Criteria	Heartburn with GERD: (1) Diagnosis of non-erosive Gastroesophageal Reflux Disease (GERD) (2) BOTH of the following: (a) Member has history of heartburn for at least 6 months (b) Heartburn symptoms are present for at least 4 days during any consecutive 7-day period (3) An inadequate response (minimum 8-week supply) or inability to tolerate TWO of the following generic proton pump inhibitors (PPI?s): omeprazole, esomeprazole, pantoprazole, lansoprazole, rabeprazole, and dexlansoprazole.
Indications	All Medically-accepted Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

VOWST 2026

Products Affected

- VOWST

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Prevention of the recurrence of Clostridioides difficile infection (PCDI): (1) Diagnosis of recurrent Clostridioides difficile infection as defined by both of the following: (a) Presence of diarrhea defined as passage of 3 or more loose bowel movements within a 24-hour period for at least 2 consecutive days (b) a positive stool test for C. difficile toxin or toxigenic C. difficile (2) Member has a history of two or more recurrent episodes of CDI within 12 months (3) Member has completed at least 10 consecutive days of one of the following antibiotic therapies 2-4 days prior to initiating Vowst: (a) oral vancomycin (b) Difacid (fidaxomicin) (4) Member has completed the recommended bowel prep (e.g. 296mL of magnesium citrate) the day before and at least 8 hours prior to initiating Vowst (5) Previous episode of CDI is under control (e.g. less than 3 unformed or loose [i.e., Bristol Stool Scale type 6-7] stools per day for at least 2 consecutive days)
Age Restrictions	(PCDI): Member is 18 years of age or older
Prescriber Restrictions	(PCDI): Prescribed by or in consultation with gastroenterologist or infectious disease specialist
Coverage Duration	(PCDI): 14 days
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

VOXZOGO 2026

Products Affected

- VOXZOGO

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

VOYDEYA 2026

Products Affected

- VOYDEYA

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

VRAYLAR 2026

Products Affected

- VRAYLAR ORAL CAPSULE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Bipolar I disorder (BD): (1) Diagnosis of bipolar I disorder (2) Inadequate response or inability to tolerate TWO of the following: aripiprazole, quetiapine, asenapine, olanzapine, paliperidone, risperidone, ziprasidone. Schizophrenia: (1) Diagnosis of schizophrenia (2) Inadequate response or inability to tolerate TWO of the following: aripiprazole, quetiapine, asenapine, olanzapine, paliperidone, risperidone, ziprasidone. Major Depressive Disorder (MDD): (1) Diagnosis of major depressive disorder and as adjunctive therapy to antidepressants (2) Inadequate response or inability to tolerate aripiprazole and quetiapine
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	(All Indications): Approve if for continuation of therapy.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

VTAMA 2026

Products Affected

- VTAMA

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

VUITY 2026

Products Affected

- VUITY

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

VYVANSE 2026

Products Affected

- VYVANSE

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

VYVGART HYTRULO SQ 2026

Products Affected

- VYVGART HYTRULO SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

WAINUA 2026

Products Affected

- WAINUA

PA Criteria	Criteria Details
Exclusion Criteria	(1) A history of liver transplant or is likely to be a candidate and (2) used in combination with any other RNA interference agents or transthyretin stabilizers
Required Medical Information	(hATTR amyloidosis)(Initial): (1) Submission of medical records (e.g. chart notes) confirming diagnosis of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) with polyneuropathy (2) Member has a transthyretin (TTR) mutation (e.g., V30M) (3) One of the following: (a) Member has a baseline familial amyloidotic polyneuropathy (FAP) stage of 1 or 2 (b) member has a baseline neuropathy impairment score (NIS) greater than or equal to 10 and less than or equal to 130 (c) Member has a baseline Karnofsky Performance Status score greater than 50 percent (4) Presence of clinical signs and symptoms of the disease (e.g., neuropathy)
Age Restrictions	
Prescriber Restrictions	(hATTR amyloidosis): Prescribed by or in consultation with a neurologist, geneticist, or professional provider specializing in the treatment of amyloidosis
Coverage Duration	12 months
Other Criteria	(hATTR amyloidosis)(Cont): (1) Member demonstrates positive clinical response to therapy (2) One of the following: (a) Member continues to have a baseline familial amyloidotic polyneuropathy (FAP) stage of 1 or 2 (b) member continues to have a baseline neuropathy impairment score (NIS) greater than or equal to 10 and less than or equal to 130 (c) Member continues to have a baseline Karnofsky Performance Status score greater than 50 percent
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

WAKIX 2026

Products Affected

- WAKIX

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

WEGOVY 2026

Products Affected

- WEGOVY

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

WILSONS DISEASE 2026

Products Affected

- CUVRIOR
- *trientine hcl oral capsule 500 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Wilson?s disease (WD)(initial): (1) Diagnosis of Wilson?s disease (i.e., hepatolenticular degeneration) (2) Inadequate response or inability to tolerate a penicillamine product
Age Restrictions	
Prescriber Restrictions	(WD): Prescribed by or in consultation with gastroenterologist, hepatologist, or liver transplant specialist.
Coverage Duration	12 months
Other Criteria	(WD) (Reauth): (1) Member demonstrates positive clinical response to therapy (e.g., reduction in 24-hour urinary copper excretion levels from baseline)
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

XDEMVY 2026

Products Affected

- XDEMVY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of treatment of demodex blepharitis
Age Restrictions	
Prescriber Restrictions	Prescribed by or in consultation with an ophthalmologist or optometrist
Coverage Duration	6 weeks
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

XELJANZ 2026

Products Affected

- XELJANZ
- XELJANZ XR

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

XENAZINE 2026

Products Affected

- XENAZINE

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

XERMELO 2026

Products Affected

- XERMELO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Carcinoid Syndrome Diarrhea (CSD)(Initial): (1) Diagnosis of carcinoid syndrome diarrhea, (2) Diarrhea is inadequately controlled by a stable dose of somatostatin analog (SSA) therapy (e.g. octreotide [Sandostatin, Sandostatin LAR], lanreotide [Somatuline Depot]) for at least 3 months, (3) Used in combination with SSA therapy
Age Restrictions	(CSD): Member is 18 years of age or older
Prescriber Restrictions	(CSD): Prescribed by or in consultation with an Oncologist, Endocrinologist, or Gastroenterologist
Coverage Duration	(Initial): 12 months (Reauth): Indefinite
Other Criteria	(CSD)(Reauth): (1) Positive clinical response to Xermelo therapy, (2) Xermelo will continue to be used in combination with SSA therapy
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

XGEVA 2026

Products Affected

- XGEVA

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

XIFAXAN 550MG 2026

Products Affected

- XIFAXAN ORAL TABLET 550 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Prophylaxis for Hepatic Encephalopathy (HE): (1) Diagnosis of hepatic disease with risk for hepatic encephalopathy (i.e. previous episode of hepatic encephalopathy, advanced liver disease, hepatocellular carcinoma), (2) Inadequate response or inability to tolerate lactulose. Irritable Bowel Syndrome (IBS): (1) Diagnosis of irritable bowels syndrome- diarrhea, (2) Inadequate response or inability to tolerate BOTH of the following: (A) ONE of the following: (i) ONE Tricyclic antidepressant or (ii)selective serotonin reuptake inhibitor and (B) dicyclomine (3): BOTH of the following: (A) Member does not exceed 3 total courses (42 days in total) of therapy, (B) Member experiences irritable bowel syndrome with diarrhea (IBS-D) symptoms. Small Bowel Bacterial Overgrowth (SBBO)/Small Intestinal Bacterial Overgrowth (SIBO) (Initial): (1) Diagnosis of Small Bowel Bacterial Overgrowth (SBBO)/Small Intestinal Bacterial Overgrowth (SIBO).
Age Restrictions	
Prescriber Restrictions	:
Coverage Duration	(HE): Indefinite. (IBS): 2 weeks. (SBBO/SIBO): Initial and Reauth: 2 weeks.
Other Criteria	(SBBO/SIBO) (Reauth): (1) Documentation of Small Bowel Bacterial Overgrowth (SBBO)/Small Intestinal Bacterial Overgrowth (SIBO) recurrence following successful initial treatment
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

XOLAIR 2026

Products Affected

- XOLAIR

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent therapy with any other biologic agents for asthma/allergic conditions (e.g., benralizumab [Fasenra], dupilumab [Dupixent], mepolizumab [Nucala])
Required Medical Information	Part D is medically necessary for: Moderate to Severe Persistent Allergic Asthma (PAA)(Initial): (1) Diagnosis of moderate to severe persistent allergic asthma (2) The individual has a positive skin test or in vitro reactivity to a perennial aeroallergen, (3) The individual has a baseline serum IgE level of between 30 IU/mL and 1300 IU/mL, (4) Inadequate response or inability to tolerate a combination of high-dose inhaled corticosteroids (ICS) with a long-acting beta-agonist (LABA). Chronic Urticaria (CU)(Initial): (1) Diagnosis of chronic urticaria (2) an inadequate response, contraindication or inability to tolerate ONE second-generation H1 antihistamine at the maximally tolerated dose in addition to ANY of the following: (a) leukotriene receptor antagonist (e.g. montelukast) (b) histamine H2-receptor antagonist (e.g. ranitidine, cimetidine, famotidine), (c) substituting to a different second- generation antihistamine, (d) systemic glucocorticosteroids or (e) cyclosporine, (3) will be used concurrently with an h1 antihistamine, unless there is contraindication or intolerance to H1 antihistamines. Nasal Polyps (NP)(Initial): (1) Diagnosis of nasal polyps. (2) Member will use concurrently with nasal corticosteroid. (3) Member had inadequate response or inability to tolerate an intranasal corticosteroid. (4) Member has a baseline serum IgE level of between 30 IU/mL and 1500 IU/mL
Age Restrictions	
Prescriber Restrictions	(PAA): Prescribed by or in consultation with an Allergist, Immunologist, or Pulmonologist. (CU):Prescribed by or in consultation with allergist/immunologist, dermatologist. (NP): Prescribed by or in consultation with an allergist, immunologist, pulmonologist, or ENT specialist. (IMFA): Prescribed by or in consultation with an Allergist or Immunologist
Coverage Duration	12 months.

PA Criteria	Criteria Details
Other Criteria	Subject to Part B vs Part D review. IgE-Mediated Food Allergy (IMFA) (initial): (1) One of the following: (A) Both of the following (i) Diagnosis of IgE-Mediated Food Allergy (ii) Clinical history of IgE Mediated Food Allergy (B) Documentation that the member has a history of severe allergic response, including anaphylaxis, following exposure to one or more foods (2) Used in conjunction with food allergen avoidance (3) Both of the following (A) Baseline (pre- Xolair treatment) serum total IgE level is greater than or equal to 30 IU/mL and less than or equal to 1850 IU/mL (B) Dosing is according to serum total IgE levels and body weight (PAA)(Reauth): (1) Documentation of positive clinical response to therapy (e.g., reduction in number of asthma exacerbations, improvement in forced expiratory volume in 1 second (FEV1), or decreased use of rescue medications). (CU)(Reauth): (1) Member's disease status has been re- evaluated since the last authorization to confirm the member's condition warrants continued treatment (2) member has experienced one or both of the following:(a) Reduction in itching severity from baseline (b) Reduction in number of hives from baseline. (NP)(Reauth): (1) Documentation of positive clinical response to therapy (e.g., reduction in nasal polyps score [NPS: 0-8 scale], improvement in nasal congestion/obstruction score [NCS: 0-3 scale]) (2) Used in combination with another agent for nasal polyps. (IMFA)(Reauth) (1) Documentation of positive clinical response to therapy (2) Used in conjunction with food allergen avoidance. (3) Dosing will continue to be based on body weight and pretreatment total IgE serum levels
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

XOLREMDI 2026

Products Affected

- XOLREMDI

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

XYREM 2026

Products Affected

- *sodium oxybate*
- XYREM

PA Criteria	Criteria Details
Exclusion Criteria	CN, EDSN: Concurrent use of sedative hypnotics and alcohol
Required Medical Information	Cataplexy in Narcolepsy (CN)(Initial): (1) Diagnosis of cataplexy with narcolepsy, (2) Diagnosis Confirmed by Polysomnography (PSG) or Multiple sleep latency test (MSLT) or prescriber provides justification that a sleep study is not feasible. Excessive Daytime Sleepiness in Narcolepsy (EDSN)(Initial): (1) Diagnosis of EDSN (Narcolepsy Type 2), (2) Diagnosis Confirmed by Polysomnography (PSG) or Multiple sleep latency test (MSLT) or prescriber provides justification that a sleep study is not feasible and (3) Inadequate response or inability to tolerate modafinil or armodafinil. (adult use only)
Age Restrictions	
Prescriber Restrictions	(CN, EDSN): Prescribed by or in consultation with a neurologist, psychiatrist, or sleep specialist.
Coverage Duration	12 months
Other Criteria	(CN, EDSN)(Reauth): (1) Documentation to support the efficacy associated with the current regimen (including but not limited to reduction in the frequency of cataplexy attacks or an improvement in the Epworth sleepiness scale), (2) Member is re-evaluated every 12 months.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

XYWAV 2026

Products Affected

- XYWAV

PA Criteria	Criteria Details
Exclusion Criteria	CN, EDSN: Concurrent use of sedative hypnotics and alcohol
Required Medical Information	Cataplexy in Narcolepsy (CN)(Initial): (1) Diagnosis of cataplexy with narcolepsy. Excessive Daytime Sleepiness in Narcolepsy (EDSN)(Initial): (1) Diagnosis of EDSN (Narcolepsy Type 2), (2) Inadequate response or inability to modafinil. Idiopathic Hypersomnia (IH) (Initial): (1) Diagnosis of Idiopathic Hypersomnia as confirmed by sleep study (unless the prescriber provides justification confirming that a sleep study would not be feasible), (2) Symptoms of excessive daytime sleepiness (e.g. nap duration of longer than 60 minutes) are present
Age Restrictions	
Prescriber Restrictions	(CN, EDSN, IH): Prescribed by or in consultation with a neurologist, psychiatrist, or sleep specialist.
Coverage Duration	12 months
Other Criteria	(CN, EDSN)(Reauth): (1) Documentation to support the efficacy associated with the current regimen (including but not limited to reduction in the frequency of cataplexy attacks or an improvement in the Epworth sleepiness scale), (2) Member is re-evaluated every 12 months. (IH) (Reauth): (1) Documentation demonstrating a reduction in symptoms of excessive daytime sleepiness associated with therapy.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

YORVIPATH 2026

Products Affected

- YORVIPATH

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ZAVESCA 2026

Products Affected

- *miglustat*
- YARGESA
- ZAVESCA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Type 1 Gaucher's Disease (T1GD)(Initial): (1) Diagnosis of mild to moderate T1GD, (2) enzyme replacement therapy is not a therapeutic option (e.g. because of allergy, hypersensitivity, or poor venous access).
Age Restrictions	(T1GD): Member is 18 years of age or older
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	(T1GD)(Reauth): Documentation of positive clinical response to therapy.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

ZAVZPRET 2026

Products Affected

- ZAVZPRET

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ZEPBOUND 2026

Products Affected

- ZEPBOUND SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

ZEPOSIA 2026

Products Affected

- ZEPOSIA
- ZEPOSIA 7-DAY STARTER PACK
- ZEPOSIA STARTER KIT ORAL CAPSULE THERAPY PACK 0.23MG & 0.46MG 0.92MG(21)

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ZILBRYSQ 2026

Products Affected

- ZILBRYSQ

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ZORYVE 0.15% CREAM 2026

Products Affected

- ZORYVE

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ZORYVE 0.3% CREAM 2026

Products Affected

- ZORYVE

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ZORYVE FOAM 2026

Products Affected

- ZORYVE

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ZTALMY 2026

Products Affected

- ZTALMY

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ZURZUVAE 2026

Products Affected

- ZURZUVAE

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ZYCLARA 2026

Products Affected

- ZYCLARA PUMP

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ZYMFENTRA SQ 2026

Products Affected

- ZYMFENTRA (2 PEN)
- ZYMFENTRA (2 SYRINGE)

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off Label Uses	UNDER CMS REVIEW
Part B Prerequisite	Yes
Prerequisite Therapy Required	Yes

Index

ABIGALE LO	117	AKEEGA	199
<i>abiraterone acetate</i>	199	AKLIEF	276
ABIRTEGA	199	ALECENSA	199
ABRILADA (1 PEN)	7	ALLZITAL	114
ABRILADA (2 SYRINGE)	7	ALTRENO	276
ACTEMRA ACTPEN	175	ALUNBRIG	199
ACTEMRA SUBCUTANEOUS	175	ALVAIZ	17
ACTHAR	4	ALYFTREK	18
ACTHAR GEL SUBCUTANEOUS PEN- INJECTOR	4	ALYQ	213
ACTIVELLA ORAL TABLET 1-0.5 MG	117	AMBIEN CR ORAL TABLET EXTENDED RELEASE 12.5 MG	119
<i>adalimumab-aacf (2 pen)</i>	9	AMBIEN ORAL TABLET 10 MG	119
<i>adalimumab-aacf (2 syringe)</i>	9	<i>ambrisentan</i>	19
<i>adalimumab-aacf(cd/uc/hs strt)</i>	9	AMJEVITA SUBCUTANEOUS SOLUTION AUTO-INJECTOR	7
<i>adalimumab-aacf(ps/uv starter)</i>	9	AMJEVITA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 40 MG/0.4ML, 40 MG/0.8ML	7
<i>adalimumab-aaty (1 pen) subcutaneous auto- injector kit 80 mg/0.8ml</i>	7	AMJEVITA-PED 10KG TO <15KG	7
<i>adalimumab-aaty (2 pen)</i>	7	AMJEVITA-PED 15KG TO <30KG	7
<i>adalimumab-aaty (2 syringe)</i>	7	<i>amphetamine sulfate</i>	89
<i>adalimumab-aaty cd/uc/hs start</i>	7	AMPYRA	20
<i>adalimumab-adaz</i>	7	AMRIX	116
<i>adalimumab-adbm (2 pen)</i>	7	ANGELIQ	117
<i>adalimumab-adbm (2 syringe)</i>	7	APOKYN SUBCUTANEOUS SOLUTION CARTRIDGE	23
<i>adalimumab-adbm(cd/uc/hs strt)</i> <i>subcutaneous auto-injector kit 40 mg/0.4ml</i>	7	<i>apomorphine hcl subcutaneous</i>	24
<i>adalimumab-adbm(ps/uv starter)</i>	7	AQNEURSA	25
<i>adalimumab-fkjp (2 pen)</i>	7	ARALAST NP INTRAVENOUS SOLUTION RECONSTITUTED 1000 MG	236
<i>adalimumab-fkjp (2 syringe)</i>	7	ARIKAYCE	26
<i>adalimumab-ryvk (2 pen)</i>	7	<i>armodafinil</i>	27
<i>adalimumab-ryvk (2 syringe)</i>	7	ASCOMP-CODEINE	114
<i>adapalene external cream</i>	276	ATRALIN	276
<i>adapalene external gel 0.3 %</i>	276	ATTRUBY	29
<i>adapalene external pad</i>	276	AUGTYRO	199
<i>adapalene-benzoyl peroxide external gel</i>	276	AUSTEDO	30
ADBRY	10	AUSTEDO XR	30
ADCIRCA	213	AUSTEDO XR PATIENT TITRATION ORAL TABLET EXTENDED RELEASE THERAPY PACK 12 & 18 & 24 & 30 MG	30
ADEMPAS	11	AUVELITY	32
AFINITOR	199	AVEED	271
AFINITOR DISPERZ	199	AVMAPKI FAKZYNJA CO-PACK	199
AFREZZA INHALATION POWDER 12 UNIT, 4 UNIT, 60X4 & 60X8 & 60X12 UNIT, 8 UNIT, 90 X 4 UNIT & 90X8 UNIT, 90 X 8 UNIT & 90X12 UNIT	12	AYVAKIT	199
AGAMREE	13	BALVERSA	199
AIMOVIG	14		
AJOVY	15		

BELBUCA BUCCAL FILM 300 MCG, 450 MCG, 600 MCG, 750 MCG, 900 MCG	111	CIMZIA SUBCUTANEOUS KIT 2 X 200 MG	50
BENLYSTA SUBCUTANEOUS	33	CINRYZE	52
BERINERT	5	<i>clemastine fumarate oral syrup</i>	114
BESREMI	171	<i>clemastine fumarate oral tablet 2.68 mg</i>	114
<i>bexarotene</i>	199, 275	CLIMARA	117
BIJUVA	117	CLIMARA PRO	117
BIMZELX	34	<i>clindamycin-tretinoin</i>	276
BIVIGAM INTRAVENOUS SOLUTION 5 GM/50ML	130	COBENFY	53
BONSITY	270	COBENFY STARTER PACK	53
<i>bosentan oral tablet</i>	35	COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MG	199
BOSULIF	199	COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MG	199
BRAFTOVI ORAL CAPSULE 75 MG	199	COMETRIQ (60 MG DAILY DOSE)	199
BRUKINSA ORAL CAPSULE	39	COPIKTRA	199
BUPHENYL ORAL POWDER 3 GM/TSP	40	CORLANOR	55
BUPHENYL ORAL TABLET	40	CORTROPHIN	4
<i>butalbital-acetaminophen oral capsule</i>	114	CORTROPHIN GEL	4
<i>butalbital-acetaminophen oral tablet 50-300 mg, 50-325 mg</i>	114	COSENTYX (300 MG DOSE)	56
<i>butalbital-apap-caff-cod</i>	114	COSENTYX SENSOREADY (300 MG)	56
<i>butalbital-apap-caffeine oral capsule</i>	114	COSENTYX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 75 MG/0.5ML	56
<i>butalbital-apap-caffeine oral tablet 50-325-40 mg</i>	114	COSENTYX UNOREADY	56
<i>butalbital-asa-caff-codeine</i>	114	COTELLIC	199
<i>butalbital-aspirin-caffeine oral capsule</i>	114	CRENESSITY	57
BYLVAY	41	CRESEMBA ORAL	58
BYLVAY (PELLETS)	41	CREXONT	59
CABOMETYX	199	CRINONE	212
CABTREO	276	CUVRIOR	311
CALQUENCE ORAL TABLET	199	<i>cyclobenzaprine hcl er</i>	116
CAMZYOS	42	<i>cyclobenzaprine hcl oral</i>	116
CAPLYTA	43	CYLTEZO (2 PEN)	7
CAPRELSA	199	CYLTEZO (2 SYRINGE)	7
CARBAGLU ORAL TABLET SOLUBLE	44	CYLTEZO-CD/UC/HS STARTER	7
<i>carbinoxamine maleate oral solution</i>	114	CYLTEZO-PSORIASIS/UV STARTER	7
<i>carbinoxamine maleate oral tablet</i>	114	CYSTADROPS	60
<i>carglumic acid oral tablet soluble</i>	44	CYSTARAN	60
<i>carisoprodol oral</i>	121	<i>dalfampridine er</i>	61
CAYSTON	45	DALVANCE	170
CERDELGA	46	DANZITEN	199
<i>chlordiazepoxide-clidinium</i>	21	<i>dapagliflozin pro-metformin er</i>	31
<i>chlorzoxazone oral</i>	114	<i>dasatinib</i>	199
CHOLBAM	47	DAURISMO	199
CIALIS ORAL TABLET 5 MG	48	DAYBUE	62
CIBINQO	49	DAYVIGO	63
CIMZIA (2 SYRINGE)	50	<i>deferasirox granules</i>	64
		<i>deferasirox oral tablet</i>	64

<i>deferasirox oral tablet soluble</i>	64	EPIDUO FORTE.....	276
<i>deferiprone</i>	96	EPSOLAY.....	86
<i>deflazacort</i>	65	ERIVEDGE.....	199
DEMEROL INJECTION SOLUTION 25 MG/ML, 50 MG/ML.....	114	ERLEADA.....	199
DEPO-TESTOSTERONE INTRAMUSCULAR SOLUTION.....	271	<i>erlotinib hcl</i>	199
DIACOMIT.....	66	ESBRIET.....	87
<i>diclofenac epolamine external</i>	69	<i>estradiol transdermal</i>	117
<i>diclofenac sodium external gel 3 %</i>	68	<i>estradiol-norethindrone acet</i>	117
DIFFERIN EXTERNAL CREAM.....	276	<i>eszopiclone oral tablet 3 mg</i>	119
DIFFERIN EXTERNAL GEL 0.3 %.....	276	EUCRISA.....	88
<i>dipyridamole oral</i>	114	EVAMIST.....	117
DIVIGEL.....	117	EVEKEO.....	89
DOJOLVI.....	70	EVENITY.....	90
DOPTELET ORAL TABLET 20 MG.....	71	<i>everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg</i>	199
DOTTI.....	117	<i>everolimus oral tablet soluble</i>	199
DUPIXENT SUBCUTANEOUS SOLUTION AUTO-INJECTOR.....	72	EVRYSDI.....	91
DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 200 MG/1.14ML, 300 MG/2ML.....	72	<i>exenatide</i>	173
DUVYZAT.....	73	EXJADE.....	64
EBGLYSS.....	74	EYSUVIS.....	93
EDLUAR SUBLINGUAL TABLET SUBLINGUAL 10 MG.....	119	FABHALTA.....	94
EGRIFTA SV.....	75	FASENRA.....	95
ELESTRIN.....	117	FASENRA PEN.....	95
<i>eltrombopag olamine</i>	224	<i>fentanyl transdermal patch 72 hour 100 mcg/hr, 25 mcg/hr, 37.5 mcg/hr, 50 mcg/hr, 62.5 mcg/hr, 75 mcg/hr, 87.5 mcg/hr</i>	111
EMFLAZA.....	76	FERRIPROX ORAL SOLUTION.....	96
EMGALITY.....	77	FERRIPROX ORAL TABLET 1000 MG.....	96
EMGALITY (300 MG DOSE).....	77	FERRIPROX TWICE-A-DAY.....	96
EMPAVELI.....	78	FILSPARI.....	97
EMSAM.....	79	FILSUVEZ.....	98
ENBREL MINI.....	80	FINTEPLA.....	99
ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML.....	80	FIORICET ORAL CAPSULE.....	114
ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE.....	80	FIORICET/CODEINE ORAL CAPSULE 50-300- 40-30 MG.....	114
ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR.....	80	FIRAZYR SUBCUTANEOUS SOLUTION PREFILLED SYRINGE.....	5
ENDARI.....	81	FIRDAPSE.....	100
ENSPRYNG.....	82	FLECTOR EXTERNAL.....	69
ENTYVIO PEN.....	83	<i>fluticasone furoate-vilanterol inhalation aerosol powder breath activated 100-25 mcg/act, 200-25 mcg/act</i>	31
EPCLUSA.....	219	<i>fluticasone-salmeterol inhalation aerosol</i>	31
EPIDIOLEX.....	85	FORTEO SUBCUTANEOUS SOLUTION PEN- INJECTOR 560 MCG/2.24ML.....	270
EPIDUO.....	276	FOTIVDA.....	199
		FRUZAQLA.....	199

FYAVOLV	117	HUMIRA-CD/UC/HS STARTER	
<i>gabapentin (once-daily)</i>	106	SUBCUTANEOUS AUTO-INJECTOR KIT 80	
GALAFOLD	101	MG/0.8ML	7
GAMMAGARD INJECTION SOLUTION 2.5		HUMIRA-PSORIASIS/UEIT STARTER	
GM/25ML	130	SUBCUTANEOUS AUTO-INJECTOR KIT	7
GAMMAGARD S/D LESS IGA	130	<i>hydrocodone bitartrate er oral capsule</i>	
GAMMAKED INJECTION SOLUTION 1		<i>extended release 12 hour</i>	3
GM/10ML	130	<i>hydrocodone bitartrate er oral tablet er 24 hour</i>	
GAMMAPLEX INTRAVENOUS SOLUTION 10		<i>abuse-deterrent</i>	3, 111
GM/100ML, 10 GM/200ML, 20 GM/200ML, 5		<i>hydromorphone hcl er oral tablet extended</i>	
GM/50ML	130	<i>release 24 hour</i>	111
GAMUNEX-C INJECTION SOLUTION 1		HYFTOR	122
GM/10ML	130	HYRIMOZ SUBCUTANEOUS SOLUTION AUTO-	
GATTEX	102	INJECTOR 40 MG/0.4ML, 80 MG/0.8ML	7
GAVRETO	199	HYRIMOZ SUBCUTANEOUS SOLUTION	
<i>gefitinib</i>	199	PREFILLED SYRINGE 10 MG/0.1ML, 20	
GENOTROPIN MINIQUICK SUBCUTANEOUS		MG/0.2ML, 40 MG/0.4ML	7
PREFILLED SYRINGE	107	HYRIMOZ-CROHNS/UC STARTER	7
GENOTROPIN SUBCUTANEOUS CARTRIDGE ..	107	HYRIMOZ-PED<40KG CROHN STARTER	7
GILOTRIF	199	HYRIMOZ-PED>/=40KG CROHN START	7
GLASSIA INTRAVENOUS SOLUTION 1000		HYRIMOZ-PLAQ PSOR/UEIT START	7
MG/50ML	236	HYSINGLA ER ORAL TABLET ER 24 HOUR	
GLEEVEC	199	ABUSE-DETERRENT 100 MG	111
GLEOSTINE ORAL CAPSULE 10 MG, 100 MG,		HYSINGLA ER ORAL TABLET ER 24 HOUR	
40 MG	199	ABUSE-DETERRENT 20 MG, 30 MG, 40 MG,	
GOCOVRI	105	60 MG, 80 MG	3
GOMEKLI	199	IBRANCE	199
GRALISE ORAL TABLET	106	<i>ibuprofen-famotidine</i>	54
GRASTEK	16	<i>icatibant acetate subcutaneous solution</i>	
HADLIMA	7	<i>prefilled syringe</i>	5
HADLIMA PUSHTOUCH	7	ICLUSIG	199
HAEGARDA	109	IDHIFA	199
HARVONI	219	ILUMYA	123
HETLIOZ	37	<i>imatinib mesylate oral</i>	199
HETLIOZ LQ	110	IMBRUVICA ORAL CAPSULE	199
HORIZANT ORAL TABLET EXTENDED		IMBRUVICA ORAL SUSPENSION	199
RELEASE	113	IMBRUVICA ORAL TABLET 140 MG, 280 MG,	
HULIO (2 PEN)	7	420 MG	199
HULIO (2 SYRINGE)	7	<i>imkeldi</i>	199
HUMATROPE INJECTION CARTRIDGE	107	IMVEXXY MAINTENANCE PACK	212
HUMIRA (2 PEN) SUBCUTANEOUS AUTO-		IMVEXXY STARTER PACK	212
INJECTOR KIT	7	INBRIJA	124
HUMIRA (2 SYRINGE) SUBCUTANEOUS		INCRELEX	125
PREFILLED SYRINGE KIT 10 MG/0.1ML, 20		INDOCIN ORAL	114
MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML	7	INDOCIN RECTAL	114
		<i>indomethacin oral suspension</i>	114
		<i>indomethacin rectal suppository 50 mg</i>	114

INGREZZA	126	LENVIMA (14 MG DAILY DOSE)	199
INLYTA	199	LENVIMA (18 MG DAILY DOSE)	199
INQOVI	199	LENVIMA (20 MG DAILY DOSE)	199
INREBIC	199	LENVIMA (24 MG DAILY DOSE)	199
<i>insulin glargine max solostar</i>	129	LENVIMA (4 MG DAILY DOSE)	199
<i>insulin glargine solostar subcutaneous solution</i>		LENVIMA (8 MG DAILY DOSE)	199
<i>pen-injector 300 unit/ml</i>	129	LETAIRIS	146
INTRAROSA	212	<i>levorphanol tartrate oral tablet 3 mg</i>	111
INZIRQO	132	<i>l-glutamine oral packet</i>	81
IQIRVO	133	LIBRAX	21
IRESSA	199	LICART EXTERNAL	69
ISTURISA ORAL TABLET 1 MG, 5 MG	134	<i>lidocaine external patch 5 %</i>	103
ITOVEBI	199	<i>liraglutide</i>	218
<i>ivabradine hcl</i>	135	<i>lisdexamphetamine dimesylate</i>	147
IWILFIN	199	LITFULO	148
JADENU	64	LIVDELZI	149
JADENU SPRINKLE	64	LIVMARLI	150
JAKAFI	199	LIVTENCITY	151
JATENZO	271	LODOCO	152
JAYPIRCA	199	LONSURF	199
JINTELI	117	LORBRENA	199
JOENJA	136	LUMAKRAS	199
JUBBONTI	217	LUMRYZ	153
JUBLIA	193	LUMRYZ STARTER PACK	153
JUXTAPID ORAL CAPSULE 10 MG, 20 MG, 30		LUNESTA ORAL TABLET 3 MG	119
MG, 5 MG	137	LUPKYNIS	154
JYNARQUE	138	LYBALVI	36
KALYDECO	139	LYLLANA	117
KERENDIA ORAL TABLET 10 MG, 20 MG	140	LYNPARZA ORAL TABLET	199
<i>ketorolac tromethamine oral</i>	118	LYRICA CR	155
KEVEYIS	67	LYTGOBI (12 MG DAILY DOSE)	199
KEVZARA	141	LYTGOBI (16 MG DAILY DOSE)	199
KINERET SUBCUTANEOUS SOLUTION		LYTGOBI (20 MG DAILY DOSE)	199
PREFILLED SYRINGE	143	MAVYRET	219
KISQALI (200 MG DOSE)	199	MEKINIST	199
KISQALI (400 MG DOSE)	199	MEKTOVI	199
KISQALI (600 MG DOSE)	199	MENOSTAR	117
KLISYRI (250 MG)	144	<i>meperidine hcl injection solution 100 mg/ml, 25</i>	
KORLYM	145	<i>mg/ml, 50 mg/ml</i>	114
KOSELUGO	199	<i>meperidine hcl oral solution</i>	114
KRAZATI	199	<i>meperidine hcl oral tablet 50 mg</i>	114
<i>lapatinib ditosylate</i>	199	<i>meprobamate</i>	114
LAZCLUZE	199	<i>metaxalone oral tablet 400 mg, 800 mg</i>	114
<i>ledipasvir-sofosbuvir</i>	219	<i>metformin hcl er (mod)</i>	92
<i>lenalidomide</i>	199	<i>metformin hcl oral tablet 625 mg, 750 mg</i>	156
LENVIMA (10 MG DAILY DOSE)	199	<i>methadone hcl oral solution</i>	111
LENVIMA (12 MG DAILY DOSE)	199	<i>methadone hcl oral tablet</i>	111

<i>methocarbamol oral tablet 1000 mg</i>	157	NUPLAZID ORAL TABLET 10 MG.....	183
<i>mifepristone oral tablet 300 mg</i>	145	NURTEC.....	184
<i>miglustat</i>	324	NUTROPIN AQ NUSPIN 10 SUBCUTANEOUS SOLUTION PEN-INJECTOR.....	107
MIMVEY.....	117	NUTROPIN AQ NUSPIN 20 SUBCUTANEOUS SOLUTION PEN-INJECTOR.....	107
MINIVELLE.....	117	NUTROPIN AQ NUSPIN 5 SUBCUTANEOUS SOLUTION PEN-INJECTOR.....	107
MIPLYFFA.....	158	NUVIGIL.....	27
<i>mirabegron er</i>	31	NUZYRA.....	170, 198
<i>modafinil oral</i>	159	OALIVA.....	185
<i>morphine sulfate er beads oral capsule extended release 24 hour 120 mg</i>	111	OCTAGAM INTRAVENOUS SOLUTION 1 GM/20ML, 2 GM/20ML.....	130
<i>morphine sulfate er oral capsule extended release 24 hour 100 mg, 60 mg, 80 mg</i>	111	<i>octreotide acetate injection solution 100 mcg/ml, 1000 mcg/ml, 200 mcg/ml, 50 mcg/ml, 500 mcg/ml</i>	186
<i>morphine sulfate er oral tablet extended release 100 mg, 200 mg, 60 mg</i>	111	ODACTRA.....	16
MOUNJARO SUBCUTANEOUS SOLUTION AUTO-INJECTOR.....	218	ODOMZO.....	199
MS CONTIN ORAL TABLET EXTENDED RELEASE 60 MG.....	111	OFEV.....	187
MULPLETA.....	161	OGSIVEO.....	199
MYALEPT.....	162	OHTUVAYRE.....	188
MYCAPSSA.....	163	OJEMDA ORAL SUSPENSION RECONSTITUTED	199
MYFEMBREE.....	164	OJEMDA ORAL TABLET 100 MG.....	199
MYTESI.....	165	OJJAARA.....	199
<i>naproxen-esomeprazole mg</i>	54	OLPRUVA (2 GM DOSE).....	189
NAYZILAM.....	6	OLPRUVA (3 GM DOSE).....	189
NEMLUVIO.....	166	OLPRUVA (4 GM DOSE).....	189
NERLYNX.....	199	OLPRUVA (5 GM DOSE).....	189
NEXAVAR.....	199	OLPRUVA (6 GM DOSE).....	189
NEXLETOL.....	167	OLPRUVA (6.67 GM DOSE).....	189
NEXLIZET.....	167	OLUMIANT.....	190
NGENLA.....	169	OMNITROPE SUBCUTANEOUS SOLUTION CARTRIDGE.....	107
<i>nilotinib hcl</i>	199	OMNITROPE SUBCUTANEOUS SOLUTION RECONSTITUTED.....	107
NINLARO.....	199	OMVOH (300 MG DOSE).....	191
NORDITROPIN FLEXPPO SUBCUTANEOUS SOLUTION PEN-INJECTOR.....	107	OMVOH SUBCUTANEOUS.....	191
<i>norethindrone-eth estradiol</i>	117	ONGENTYS.....	192
NORGESIC.....	120	ONUREG.....	199
<i>norgesic forte</i>	120	ONYDA XR.....	194
NOURIANZ.....	178	OPIPZA.....	195
NOXAFIL ORAL PACKET.....	180	OPSUMIT.....	202
NOXAFIL ORAL SUSPENSION.....	179	OPSYNVI.....	196
NUBEQA.....	199	OPZELURA.....	197
NUCALA.....	181	ORENCIA CLICKJECT.....	203
NUCYNTA ER.....	3, 111		
NUCYNTA ORAL TABLET 100 MG, 75 MG.....	111		
NUEDEXTA.....	182		
NUPLAZID ORAL CAPSULE.....	183		

ORENCIA SUBCUTANEOUS SOLUTION		<i>posaconazole oral</i>	179
PREFILLED SYRINGE	203	PRALUENT SUBCUTANEOUS SOLUTION	
ORENITRAM	202	AUTO-INJECTOR	215
ORENITRAM MONTH 1	202	<i>pregabalin er</i>	155
ORENITRAM MONTH 2	202	PREMARIN ORAL	117
ORENITRAM MONTH 3	202	<i>pretomanid</i>	222
ORGOVYX	199	PRIVIGEN INTRAVENOUS SOLUTION 20	
ORIAHNN	204	GM/200ML	130
ORLISSA	205	PROCYSBI ORAL PACKET	223
ORKAMBI	206	PROLASTIN-C INTRAVENOUS SOLUTION	236
ORLADEYO	207	PROLIA SUBCUTANEOUS SOLUTION	
ORMALVI	67	PREFILLED SYRINGE	172
<i>orphenadrine citrate er</i>	21	PROMACTA	224
<i>orphenadrine-aspirin-caffeine oral tablet 25-</i>		<i>promethazine hcl oral solution 6.25 mg/5ml</i>	114
<i>385-30 mg</i>	120	<i>promethazine hcl oral tablet</i>	21
ORSERDU	199	<i>promethazine hcl rectal suppository 12.5 mg,</i>	
OSPHENA	212	<i>25 mg</i>	21
OTEZLA	208	<i>promethazine-phenylephrine</i>	21
OTULFI SUBCUTANEOUS	176	PROMETHEGAN RECTAL SUPPOSITORY 25	
OXERVATE	210	MG, 50 MG	21
<i>oxycodone hcl oral tablet abuse-deterrent</i>	3, 111	PROVIGIL	159
OXYCONTIN ORAL TABLET ER 12 HOUR		PYRUKYND	226
ABUSE-DETERRENT	3, 111	PYRUKYND TAPER PACK	226
<i>oxymorphone hcl er oral tablet extended release</i>		PYZCHIVA SUBCUTANEOUS SOLUTION	
<i>12 hour 20 mg, 30 mg</i>	111	PREFILLED SYRINGE	176
<i>oxymorphone hcl er oral tablet extended release</i>		QBREXZA	227
<i>12 hour 40 mg</i>	111	QINLOCK	199
<i>oxymorphone hcl oral tablet 10 mg</i>	111	<i>quinine sulfate oral</i>	228
OXYTROL	209	QULIPTA	229
OZEMPIC (0.25 OR 0.5 MG/DOSE)		QUVIVIQ	230
SUBCUTANEOUS SOLUTION PEN-INJECTOR 2		RADICAVA ORS STARTER KIT	231
MG/3ML	218	RALDESY	232
OZEMPIC (1 MG/DOSE) SUBCUTANEOUS		RASUVO SUBCUTANEOUS SOLUTION AUTO-	
SOLUTION PEN-INJECTOR 4 MG/3ML	218	INJECTOR 10 MG/0.2ML, 12.5 MG/0.25ML, 15	
OZEMPIC (2 MG/DOSE)	218	MG/0.3ML, 17.5 MG/0.35ML, 20 MG/0.4ML,	
PALYNZIQ	211	22.5 MG/0.45ML, 25 MG/0.5ML, 30	
PANZYGA	130	MG/0.6ML, 7.5 MG/0.15ML	128
PAXIL ORAL TABLET	22	RAVICTI	233
<i>pazopanib hcl</i>	199	RECORLEV	234
PEMAZYRE	199	REPATHA	235
<i>pentazocine-naloxone hcl</i>	114	REPATHA PUSHTRONEX SYSTEM	235
PHEBURANE	214	REPATHA SURECLICK	235
PIQRAY (200 MG DAILY DOSE)	199	RETEVMO ORAL TABLET	199
PIQRAY (250 MG DAILY DOSE)	199	RETIN-A	276
PIQRAY (300 MG DAILY DOSE)	199	RETIN-A MICRO	276
<i>pirfenidone</i>	87	RETIN-A MICRO PUMP EXTERNAL GEL 0.06	
POMALYST	199	%, 0.08 %	276

REVATIO ORAL TABLET	245	<i>sodium phenylbutyrate oral tablet</i>	104
REVLIMID	199	<i>sofosbuvir-velpatasvir</i>	219
REVUFORJ	199	SOGROYA	253
REXULTI	237	SOHONOS	254
REZDIFFRA	238	SOLQUA	173
REZLIDHIA	199	SOMA	121
REZUROCK	239	<i>sorafenib tosylate</i>	199
RINVOQ	240	SOTYKTU	256
RINVOQ LQ	241	SOVALDI	174
RIVFLOZA	242	SPEVIGO SUBCUTANEOUS SOLUTION	
ROMVIMZA	199	PREFILLED SYRINGE 150 MG/ML	257
ROXYBOND	3, 111	SPRIX	118
ROZLYTREK	199	SPRYCEL	199
RUBRACA	199	STELARA SUBCUTANEOUS SOLUTION 45	
RUCONEST	5	MG/0.5ML	176
RYBELSUS	218	STELARA SUBCUTANEOUS SOLUTION	
RYDAPT	199	PREFILLED SYRINGE	176
RYVENT	114	STEQUEYMA SUBCUTANEOUS	176
SAJAZIR SUBCUTANEOUS SOLUTION		STIVARGA	199
PREFILLED SYRINGE	5	<i>sunitinib malate</i>	199
SAMSCA	38	SUNOSI	258
SANDOSTATIN INJECTION SOLUTION 100		SUTENT	199
MCG/ML, 50 MCG/ML, 500 MCG/ML	186	SYMDEKO	259
SCSEMBLIX	199	TABRECTA	199
SELARSDI SUBCUTANEOUS	176	<i>tadalafil (pah)</i>	213
SEROSTIM SUBCUTANEOUS SOLUTION		<i>tadalafil oral tablet 2.5 mg, 5 mg</i>	260
RECONSTITUTED 4 MG, 5 MG, 6 MG	243	TADLIQ	261
SIGNIFOR	244	TAFINLAR	199
<i>sildenafil citrate oral suspension reconstituted</i>	245	TAGRISSO	199
<i>sildenafil citrate oral tablet 20 mg</i>	245	TAKHZYRO	263
SILIQ	246	TALTZ	264
SIMLANDI (1 PEN) SUBCUTANEOUS AUTO-		TALZENNA	199
INJECTOR KIT 80 MG/0.8ML	7	TANLOR	157
SIMLANDI (1 SYRINGE)	7	TARGRETIN	199, 275
SIMLANDI (2 PEN)	7	TARPEYO	266
SIMLANDI (2 SYRINGE)	7	TASIGNA	199
SIMPONI SUBCUTANEOUS SOLUTION AUTO-		<i>tasimelteon</i>	267
INJECTOR	247	<i>tavaborole</i>	193
SIMPONI SUBCUTANEOUS SOLUTION		TAVALISSE	268
PREFILLED SYRINGE	247	TAVNEOS	269
SIRTURO	249	TAZVERIK	199
SIVEXTRO	170, 198	TENCON ORAL TABLET 50-325 MG	114
SKYCLARYS	250	TEPMETKO	199
SKYRIZI PEN	251	<i>teriparatide subcutaneous solution pen-injector</i>	
SKYRIZI SUBCUTANEOUS	251	<i>560 mcg/2.24ml</i>	270
SKYTROFA	252	<i>testosterone cypionate intramuscular solution</i>	
<i>sodium oxybate</i>	321	<i>100 mg/ml, 200 mg/ml</i>	271

<i>testosterone enanthate intramuscular solution</i>	271	<i>ustekinumab subcutaneous</i>	176
<i>testosterone transdermal gel 10 mg/act (2%), 12.5 mg/act (1%), 20.25 mg/1.25gm (1.62%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 40.5 mg/2.5gm (1.62%), 50 mg/5gm (1%)</i>	271	<i>ustekinumab-ttwe subcutaneous</i>	176
<i>testosterone transdermal solution</i>	271	VABOMERE	170
<i>tetrabenazine</i>	273	VALCHLOR	275
THALOMID ORAL CAPSULE 100 MG, 50 MG...	199	VALTOCO 10 MG DOSE	6
TIBSOVO	199	VALTOCO 15 MG DOSE NASAL LIQUID THERAPY PACK 2 X 7.5 MG/0.1ML	6
TLANDO	271	VALTOCO 20 MG DOSE NASAL LIQUID THERAPY PACK 2 X 10 MG/0.1ML	6
TOBI PODHALER	127	VALTOCO 5 MG DOSE	6
<i>tolvaptan</i>	138, 274	VANFLYTA	199
TORPENZ	199	VECAMYL	288
TRACLEER	277	VELSIPITY	289
TRELSTAR MIXJECT	171	VENCLEXTA	199
TREMFYA CROHNS INDUCTION	278	VENCLEXTA STARTING PACK	199
TREMFYA ONE-PRESS	278	VEOZAH	290
TREMFYA PEN SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200 MG/2ML	278	VERKAZIA	291
TREMFYA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE	278	VERQUVO	292
<i>tretinoin external</i>	276	VERZENIO	199
<i>tretinoin microsphere external gel 0.04 %, 0.1 %</i>	276	VESICARE	209
<i>tretinoin microsphere pump external gel 0.08 %</i>	276	VFEND IV	212
<i>trientine hcl oral capsule 500 mg</i>	311	VICTOZA SUBCUTANEOUS SOLUTION PEN- INJECTOR	173
TRIKAFTA	280	VIGAFYDE	293
TRULICITY SUBCUTANEOUS SOLUTION AUTO-INJECTOR	218	VIJOICE	294
TRUQAP ORAL TABLET 200 MG	199	VITRAKVI	199
TRYNGOLZA	281	VIVELLE-DOT	117
TRYVIO	282	VIVJOA	295
TUKYSA	199	VIZIMPRO	199
TURALIO ORAL CAPSULE 125 MG	199	VONJO	199
TWYNEO	276	VOQUEZNA	297
TYENNE SUBCUTANEOUS	220	VOQUEZNA DUAL PAK	296
TYKERB	199	VOQUEZNA TRIPLE PAK	296
TYMLOS	283	VORANIGO	199
TYVASO DPI MAINTENANCE KIT INHALATION POWDER 16 MCG, 32 MCG, 48 MCG, 64 MCG	285	<i>voriconazole intravenous</i>	212
TYVASO DPI TITRATION KIT INHALATION POWDER 16 & 32 & 48 MCG	285	VOSEVI	174
UBRELVY	286	VOTRIENT	199
UNDECATREX	271	VOWST	299
UPTRAVI ORAL	287	VOXZOGO	300
UPTRAVI TITRATION	287	VOYDEYA	301
		VRAYLAR ORAL CAPSULE	302
		VTAMA	303
		VUITY	304
		VYNDAMAX	262
		VYNDAQEL	262
		VYVANSE	305

VYVGART HYTRULO SUBCUTANEOUS SOLUTION PREFILLED SYRINGE.....	306	ZELBORAF.....	199
WAINUA.....	307	ZEMAIRA INTRAVENOUS SOLUTION RECONSTITUTED 1000 MG.....	236
WAKIX.....	309	ZEMDRI.....	170
WEGOVY.....	310	ZEPATIER.....	174
WELIREG.....	199	ZEPBOUND SUBCUTANEOUS SOLUTION AUTO-INJECTOR.....	326
WEZLANA SUBCUTANEOUS.....	176	ZEPOSIA.....	327
WINREVAIR.....	255	ZEPOSIA 7-DAY STARTER PACK.....	327
XALKORI.....	199	ZEPOSIA STARTER KIT ORAL CAPSULE THERAPY PACK 0.23MG &0.46MG 0.92MG(21).....	327
XDEMVI.....	312	ZERBAXA.....	170
XELJANZ.....	313	ZIANA.....	276
XELJANZ XR.....	313	ZILBRYSQ.....	328
XENAZINE.....	314	ZOLINZA.....	199
XERMELO.....	315	<i>zolpidem tartrate er oral tablet extended release 12.5 mg.....</i>	119
XGEVA.....	316	<i>zolpidem tartrate oral capsule.....</i>	119
XIFAXAN ORAL TABLET 550 MG.....	317	<i>zolpidem tartrate oral tablet 10 mg.....</i>	119
XOLAIR.....	318	<i>zolpidem tartrate sublingual tablet sublingual 3.5 mg.....</i>	119
XOLREMDI.....	320	ZOMACTON.....	107
XOSPATA.....	199	ZORYVE.....	329, 330, 331
XPOVIO (100 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 50 MG.....	199	ZTALMY.....	332
XPOVIO (40 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 10 MG.....	199	ZTLIDO.....	212
XPOVIO (40 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 40 MG.....	199	ZURZUVAE.....	333
XPOVIO (60 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 60 MG.....	199	ZYCLARA PUMP.....	334
XPOVIO (60 MG TWICE WEEKLY).....	199	ZYDELIG.....	199
XPOVIO (80 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG.....	199	ZYKADIA ORAL TABLET.....	199
XPOVIO (80 MG TWICE WEEKLY).....	199	ZYMFENTRA (2 PEN).....	335
XTAMPZA ER.....	3, 111	ZYMFENTRA (2 SYRINGE).....	335
XTANDI.....	199	ZYPREXA ORAL TABLET 2.5 MG, 20 MG, 5 MG..	36
XULTOPHY.....	173	ZYTIGA.....	199
XYOSTED.....	271		
XYREM.....	321		
XYWAV.....	322		
YARGESA.....	324		
YESINTEK SUBCUTANEOUS.....	221		
YONSA.....	199		
YORVIPATH.....	323		
YUFLYMA (1 PEN).....	7		
YUFLYMA (2 SYRINGE).....	7		
YUFLYMA-CD/UC/HS STARTER.....	7		
ZAVESCA.....	324		
ZAVZPRET.....	325		
ZEJULA ORAL TABLET.....	199		